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Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest human 
malignancies with an extremely poor 5-year survival rate of below 5%. Surgical resection 
is the most effective treatment of choice because chemotherapy and radiation therapy do 
not improve life expectancy. Residual tumor after PDAC surgery is common due to a lack 
of PDAC targeted intraoperative contrast agents to confirm clear margins.  
Fluorescence imaging has the potential to improve surgery outcome and PDAC 
patients’ survival rate via the use of highly PDAC-specific molecular probes to facilitate 
tumor identification. This thesis describes the application of a focused library of 
benzoxanthene fluorophores for PDAC margin assessment. This work shows the utility of 
fluorophore 12 in the ex vivo staining of human PDAC tissue. When 12 was used for ex 
vivo staining of healthy pancreas and PDAC tissue, it displayed visually higher localization 
in the PDAC-associated ductal epithelial cells compared to the healthy tissue. We 
optimized the ex vivo staining conditions such as fluorophore concentration, fluorophore 
incubation and washing time, for clinical translation. A receiver operator characteristic 
(ROC) curve analysis was used as a non-subjective evaluation for effective contrast 
between cancer and healthy tissue, confirming high throughput and efficient screening for 
the investigated parameters.  
The need for dyes that are active in the near-infrared region (NIR) region (>700 
nm) and have large Stoke shifts led to the design and synthesis of a benzo[a]xanthene 




reduced photobleaching of the fluorophore. The benzo[a]xanthene library shows at least 
two-fold enhanced brightness compared to the benzo[c]xanthene library, along with no 
significant bathochromic shift, as predicted by density functional theory (DFT) 
calculations. Compound 8, a regioisomer of 12 with analogous physicochemical properties, 
showed selectivity for PDAC but was not as optimal as 12. The functionalization of the 
benzo[c]xanthene chromophore with a cyanine chromophore moiety was proposed towards 
developing NIR-active fluorophores. The synthesis of cyanine-xanthene hybrids was 
begun. Once the synthesis is optimized, the hybrid dyes will be screened for PDAC 
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Chapter 1: Introduction 
 
Pancreatic cancer 
 Pancreatic Ductal Adenocarcinoma (PDAC) is the most prevalent form of 
pancreatic cancer, accounting for over 90 % of all pancreatic cancer cases.1 Approximately 
57,600 people will be diagnosed with pancreatic cancer and 47,050 of these patients will 
die. Pancreatic cancer accounts for ~3% of all cancer cases in the US and ~ 7% of all cancer 
deaths.2 Due to the late diagnosis of PDAC, conventional treatments such as chemotherapy 
and radiotherapy are ineffective, leaving surgery as the relatively most effective cure.3 
White light visualization, palpation and rapid frozen section analysis (FSA) are some of 
the methods used during PDAC surgery to aid complete resection of the tumor.4 Due, in 
large part, to a lack of commercially available PDAC specific contrast agents, up to 75% 
of patients are left with residual disease after surgery.5 This high number highlights the 
current inability to detect the true delineation of the tumor extent during surgery.6 There is 
thus a need to develop PDAC contrast agents that can be used during surgery for margin 
assessment. Moreover, PDAC-specific probes may potentially be used for intraoperative 
FSA.7 Intraoperative frozen section examination is a common technique to assess tumor 
involvement (R1) during pancreatic cancer surgery.8 The goal is to achieve clear margins, 
where there is no tumor involvement (R0), after surgery.5 
To develop such contrast agents it is important to understand the microenvironment 




replaced by fibrous tissue in cancer.1 The stroma can act as a “fortress” blocking the entry 
of small molecules to the ducts with adenocarcinoma.4  
The progression to cancer starts with precursor lesions called the pancreatic 
intraepithelial neoplasia (PanIN) which, by step-wise mutations, start from low-grade 
hyperplasia (PanIN-1 to PanIN-2) of the normal cells to high grade dysplasia/carcinoma in 
situ (PanIN-3). Once cancer evolves, the stroma comprises up to 90% of the mass (Figure 
1).9 The components of the stroma include fibroblasts, leukocytes, endothelial cells and 
extracellular matrix proteins.10 
Figure 1. Hematoxylin & Eosin stain of normal, precancerous lesions (PanIN 1-3) and cancer tissue. 
 Additionally, the mitochondrial membrane potential of cancer cells is relatively 
more negative compared to normal cells.11 This is due to mitochondrial DNA mutations. 
The differential membrane potential between cancer cells and normal cells has allowed for 
the use of cationic small molecules to study mitochondrial metabolism and also as potential 
anticancer drugs.12-17  
In the work described herein, cationic probes are used as contrast imaging agents. 
The synthetic lipophilic cationic dyes selectively accumulate in the mitochondria of cancer 
cells compared to normal cells, enabling contrast between cancer and normal cells. 




moment are parameters for investigation towards the design and synthesis of inherent 
targeting contrast agents to achieve selectivity. 
 
Probe Design for PDAC Imaging 
To address the characteristic features of the PDAC microenvironment and the 
phenotypic properties of cancer cells (e.g., elevated mitochondrial membrane potential), a 
series of probes were systematically designed with a focus on their physicochemical 
properties of the dyes.4,11 Charge, lipophilicity, charge density, polar surface area and 
dipole moment are descriptors used in the drug development industry to achieve optimum 
biodistribution and tissue targeting. The descriptors as described by the Lipinski rule of 
five and the Verber rules (Figure 2) embody a starting framework to help understand 
optimal tissue targeting. Throughout the work herein, the physicochemical properties of 
the synthetic dyes served as a context to begin to understand optimal tissue targeting.18-20 
 
Table 1. Guidelines for the physicochemical properties of drugs described by Lipinski 




 The Xanthene chromophore (Figure 2) acts a great platform to develop probes with 




modifications to the chromophore that include changing the angle of annulation and 
changing the position of the polar groups (R2 and R3) allows for the synthesis of xanthene-
based probes with different lipophilicities, molecular sizes, charges (ionization states) and 
polar surface areas.21-25 These modifications not only alter the physicochemical properties 
of the dyes but the photophysical properties as well, which this work has also focused on. 
 
Figure 2. Altering angle of annulation and transposition of polar groups (R2 and R3) to modulate 




  The goals of this investigation are to i) design and synthesize libraries of xanthene-
based fluorophores to be screened for PDAC specificity and evaluated for other properties, 
ii) develop a staining protocol for intraoperative PDAC margin assessment to ensure 
complete resection of cancer, and iii) develop a quantitative method to objectively measure 
PDAC selectivity. Previously, our group designed and synthesized a library of R2-
substituted benzo[c]xanthene fluorophores (Figure 3) with physiochemical properties 





Figure 3. R2-substituted benzo[c]xanthene library of fluorophores. 
Properties such as molecular weight, formal charge, lipophilicity, polar surface area 
and others, were used as descriptors to understand PDAC targeting. A unique characteristic 
of PDAC tissue compared to healthy pancreas tissue is the high fibrous tissue (stroma) 
surrounding ducts with adenocarcinoma, compared to normal ducts surrounded by acini 
cells. The “stromal fortress,” serves as a barrier believed to promote resistance to 
chemotherapy. In a genetically-engineered PDAC murine model (KMC mice), compound 
12 from the library shown in Figure 3 exhibited inherent localization in ductal 
adenocarcinoma versus the surrounding stroma tissue. Compound 12 showed the highest 
signal-to-background (S/B) ratio in both in vivo (tail vein injection) and ex vivo (frozen 
section tissue) staining of PDAC tissue compared to other candidates from the library. 
Importantly, compound 12 does not possess a conjugated targeting moiety/ligand therefore 
shows inherent PDAC-specificity.23  
In this work, pre-staged human frozen tissue sections were purchased from Origene 
Inc., and 12 enabled the selective staining and quantification of signal intensity in PDAC 




a developed Matlab code allowed for an objective analysis of the staining in healthy human 
pancreas tissue versus the PDAC human tissue. The ability to selectively stain for PanIN 
has the potential to enable early monitoring and elucidation on PDAC progression. 
Moreover, the staining procedure was optimized to obtain a sample for quantitative 
imaging within 15 min, in keeping with the timing of intraoperative H&E staining (a gold 
standard for pathology) and the current clinical workflow. Utilizing the optimized staining 
protocol in conjunction with quantitative fluorescence using 12 has the potential to ensure 
clear margins after PDAC surgery to help address the current low survival rates from 
PDAC surgery.26 
The need for dyes that are active in the near-infrared region (NIR) region (>700 
nm) and have large Stoke shifts led to the design and synthesis of a novel benzo[a]xanthene 
library (Figure 4).24 Among other advantages of imaging in the NIR include, reduced 
autofluorescence and reduced tissue damage due to the use of light with low energy to 
excite the fluorophore.27 
 
Figure 4. Type [a] benzoxanthene library. 
The benzo[a]xanthene library displayed at least 2-fold enhanced brightness 
compared to the benzo[c]xanthene library, and no significant bathochromic shift, as was 




with analogous physicochemical properties, also shows PDAC selectivity with compound 
12 a more optimal candidate.  
The functionalization of the benzo[c]xanthene chromophore with other 
chromophore moieties is another strategy that was used to develop NIR-active cyanine-
xanthene probes (Figure 5) in this work. Cyanine-xanthene hybrids are currently being 
synthesized and the preliminary synthesis is promising. These hybrid dyes will be screened 
for PDAC selectivity and subsequently used for PDAC margin assessment. 
 
Figure 5. A library of cyanine-xanthene library. 
Research Value 
 The outcome of this work will contribute to the field of inherent tissue targeting of 
PDAC, using probes without the need for any antibodies or related biomolecules 
conjugated as targeting ligands. The absence of a targeting ligand allows for attaining 




PDAC surgery. This intraoperative margin assessment could greatly improve the surgery 
outcome and in turn increase the survival rates of PDAC patients after surgery.  
This work also led to a novel library of benzo[a]xanthene probes with atypical 
photophysical trends compared to all pH-sensitive xanthene dyes reported thus far. The 
successful functionalization of a xanthene chromophore with cyanine dye moieties will 
address the inherent photophysical limitations of both classes by allowing for synergistic 
enhancement of photophysical properties. The ease of structure modifications will also 
allow for further structure-activity-relationship investigations of inherent tissue targeting. 
Lastly, the strategy utilized herein of inherent tissue targeting can be applied to the 
development of fluorescent analogs for other surgically treated cancer type, including 
breast, prostate and colon cancer. 
Specific Chapter Summaries 
 Chapter 2 reports on the use of 12 to stain human PDAC tissue and the precursor 
PanIN lesions. I also show the development of an objective quantitative method based on 
Matlab code for measuring effective PDAC contrast. I show results of the optimization of 
an ex vivo staining protocol and its potential compatibility to the current PDAC surgery 
workflow. 
 Chapter 3 expands on the concept of inherent tissue targeting by reporting a novel 
library of benzo[a]xanthene dyes that are regioisomers of benzo[c]xanthenes. The goal of 
synthesizing the benzo[a]xanthene library was to study the effects of changing the angle of 
annulation on the photophysical and inherent tissue targeting properties. I also report on 




Also reported is an effective and efficient synthetic method I developed to allow for 
bioconjugation of the benzo[a]xanthene fluorophores to targeting ligands and the 
subsequent conjugation of compound 8 from the library to microtubule targeting antibody. 
 Chapter 4 focuses on the synthetic strategies employed to synthesize NIR-active 
cyanine-xanthene hybrid dyes. The cross-coupling between benzo[c]xanthene ditriflate 
and a conjugated alkene afforded the desired cyanine-xanthene hybrid probe. 
Chapter 5 summarizes the results and discusses the direction for future work. 
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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent and deadly form 
of pancreas cancer. Previously, utilizing compound 12, a fluorophore with inherent PDAC 
selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current 
study, human PDAC tissue is targeted. Compound 12 selectively stains ducts of the 
adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen 
tissue sections with high contrast. To enhance the potential of 12 for intraoperative 
applications, the ex vivo staining protocol was optimized for rapid margin assessment, with 
a final staining time of ~15 min. To measure diagnostic performance, the area under a 
receiver operating characteristic (ROC) curve was measured for the identification of ductal 
adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative 
determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in 
human tissue array samples.  
 INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic 
cancer, accounting for approximately 90% of all cases.1 With a five-year survival rate < 




Although < 20% of PDAC patients qualify for surgery, it remains the only effective 
treatment option.1 Resection margin (RM) status is a key predictive factor in a patient’s 
post-surgery survival.3 To assess margin clearance (R0) versus margin involvement (R1), 
surgeons currently rely on basic tools such as white light visualization and palpation for 
guidance during surgery. Intraoperative frozen section analysis (FSA) is also performed in 
many cases, wherein a tissue margin sample, stained with hematoxylin and eosin (H&E), 
is assessed by a pathologist.4-6 However, H&E staining is not quantifiable and is 
nonspecific for PDAC and does not adequately detect microscopic tumors.7 These 
techniques have resulted in high resection margin involvement (> 50 % R1) in PDAC 
patients. Patient prognosis is generally poor.8 
Fluorescence imaging using PDAC-specific fluorophores offers an opportunity to 
improve current intraoperative margin assessment.9-11 It has the potential to provide rapid, 
accurate ex vivo confirmation of negative margin (R0) status during surgery. Our lab 
previously reported the synthesis of a library of xanthene fluorophores to investigate the 
targeted imaging of PDAC in a genetic-engineered PDAC murine model (KMC mice). 
Compound 12 from the library showed excellent selectivity and signal-to-background 
(S/B) ratio in both in vivo (tail vein injection) and ex vivo (FSA) staining of PDAC tissue. 
Compound 12 does not possess a conjugated targeting moiety.9 It was designed with 
physiochemical properties intended to promote its inherent selectivity for epithelial ductal 
adenocarcinoma versus the surrounding stroma tissue.12-14 A unique characteristic of 
PDAC is that most of the tumor volume does not consist of tumor cells, but rather is 




barrier that, for instance, has been noted as a potential reason that PDAC is intrinsically 
resistant to chemotherapy.15 
In the current study, we show that 12 enables the selective staining and 
quantification of PDAC in human frozen tissue samples, including the most common 
PDAC precursor lesions, pancreatic intraepithelial neoplasia (PanIN). Moreover, we 
optimized the procedure to obtain a sample for quantitative imaging within 15 min, in 
keeping with intraoperative H&E staining and the current clinical workflow.  
 
 MATERIALS & METHODS 
  General Study Design 
The primary goal of this study was to identify a fluorescence staining protocol that provides 
the highest diagnostic performance within a clinically relevant time frame. These optimum 
conditions were applied to human PDAC specimen purchased from Origene Inc. 
Optimization was accomplished by fluorescence imaging with different staining 
concentrations (125, 250 and 500 µM) and fluorophore incubation times (1, 5, 10 and 40 
minutes), in triplicate (Figure S2, supplementary information). The performance was 
assessed using ROC curve analysis, with the area under the curve (AUC) as a metric for 
the contrast between PDAC versus surrounding stromal tissue. The mouse tissue for 
protocol optimization studies was from a genetically engineered mouse model of PDAC 
(KMC mouse model) used in a previous study by our group.9 The optimized conditions 




normal tissue, with 60% exocrine epithelium, 20% endocrine epithelium and 20% ducts; 
(ii) pancreatic intraepithelial neoplasia non-tumor structures (PanIN) comprised of 10% 
exocrine epithelium, 5% endocrine epithelium and 85% ducts; (iii) moderately 
differentiated PDAC tissue with a tumor grade of G3, and; (iv) poorly differentiated tumor 
tissue with a tumor grade of G2. Compound 12 was used in all experiments (Figure 1).9 
 
 
Figure 1. Compound 12. 
 
 
 Ex vivo fluorescence microscopy  
The resected pancreas tissue from healthy control mice and the KMC mice models with 
PDAC tumor-bearing mice were fixed with 2% PFA for 12 h, flash frozen in optimal 
cutting temperature (OCT) compound with liquid N2, and stored at −80 °C. Cryosections 
were cut at 10 microns onto Superfrost Plus slides (Fisherbrand, Fisher Scientific). Serial 
sections were obtained and used for ex vivo staining. Images were acquired on an Axio 
Observer inverted fluorescence microscope (Zeiss, Thornwood, NY) at 20× magnification. 
A PhotoFluor II was used and filtered using a 545 ± 12.5 bandpass excitation filter for 12. 




35 bandpass emission filter. Whole tissue images were acquired using Zeiss Axioscan Z.1 
slide scanner (Carl Zeiss) at 20× magnification. The fluorescence signal was optimized at 
the start of the study to not oversaturate the signal. For a standardized comparison, the 
power of Colibri 7 light source and integration times of the Hamamatsu ORCA Flash4 
camera (Hamamatsu Photonics) were kept constant for all samples. The imaging on the 
slides was performed with identical image acquisition settings after staining overnight. 
 
 Statistical Analysis 
Statistical analysis was performed using MatLab. To quantify tumor-to-stroma pancreas 
tissue diagnostic detection, ROC curves were generated for ductal adenocarcinoma versus 
stroma tissue. As a control, ROC curves were generated for healthy acinar tissue versus 
healthy acinar tissue. ROC curves and corresponding AUC measurements were calculated 
on a pixel-by-pixel basis by running a threshold value across individual pixel values for 
each tissue type and measuring the true-positive and false-negative fractions of 
adenocarcinoma ductal tissue over surrounding stromal tissue at each threshold increment. 
Histogram plots of the fluorescence image pixel values for ductal and stromal pixels were 
generated and plotted. Statistical significance between staining conditions was determined 
using the method described by Hanley and McNeil16 with standard error measurements and 
correlation coefficients for pixel intensity values for each condition used for z-score value 






 Original ex vivo Direct Fluorophore Staining Protocol 
 
The initial wash to remove excess OCT was done by covering each tissue sample with 
PBS. After 2 min, it was removed with vacuum. The tissue samples were fixed with 2% 
PFA at rt. for 15 min and washed 3× using PBS with 0.1% Tween-20 for 5 min. Slides 
were incubated with fluorophore formulation, (10% dimethyl sulfoxide DMSO (control) 
or 10% DMSO fluorophore solution (dependent on specific concentration of fluorophore), 
5% Kolliphor EL, 85% of 75/25 serum/PBS) for 40 min at rt.17 Slides were covered to 
prevent photobleaching. Excess fluorophore was removed through two 5 min rinses with 
PBS. Fluorophore post-fixing was done using 2% PFA for 15 min and washed 1× with 
PBS for 5 min. After removing excess PBS samples were mounted with fluoromount. The 
coverslip was placed onto tissue, making sure no air bubbles were present. The coverslips 
were sealed with colorless nail polish. The slides were stored at 20 ºC. The total time for 
the staining protocol was 1 h 42 min. 
 
 Modified ex vivo direct fluorophore staining protocol 
 
The initial rinse was done by flash washing each tissue sample with PBS with rapid 
removal with vacuum. The tissue samples were fixed with 2% PFA at rt for 5 min, rinsed 
rapidly 3× using PBS with 0.1% Tween-20. Slides were incubated with fluorophore 
formulation (5 min, rt). Slides were covered to prevent photobleaching. The excess 




using 2% PFA for 5 min and with a 1× wash with PBS. Excess PBS was removed and 
samples were mounted with fluoromount. The coverslip was placed onto tissue, ensuring 
no air bubbles covered the samples. The coverslips were sealed with colorless nail polish. 
The slides were stored at 20 ºC. The total time for the optimized protocol was 15 min. 
 RESULTS AND DISCUSSION 
 Staining of human PDAC tissue 
Our lab previously showed that 12 enabled the imaging of PDAC in a genetically 
engineered mouse model with high specificity both in vivo and ex vivo. Figure 2 shows the 
ex vivo efficacy of 12 in visualizing human PDAC, showing increased accumulation in the 
ductal adenocarcinoma epithelial tissue compared to the surrounding stroma tissue. In 
normal tissue, 12 shows a homogenous accumulation as also previously reported in our 
mouse model work.9  
 
Figure 2. Ex vivo images from frozen sections of resected human tissue stained with compound 12. Normal 
tissue displayed homogeneous staining in acinar cells. PDAC tissue displayed high contrast between the 
ductal and stroma tissue. White arrows are pointing to the selectively stained ducts with adenocarcinoma 
surrounded by blue starred unstained stroma tissue regions of PDAC.  
 
To obtain a more complete picture of the inherent accumulation of 12 in ductal 
adenocarcinoma versus the stroma tissue, whole tissue images were obtained using Zeiss 
Axioscan Z.1 slide scanner (Figure 3). The homogeneous staining of healthy human 




adenocarcinoma versus stroma in the human PDAC pancreas tissue is clear. Two different 
grades of human PDAC pancreas tissue were examined. Figure 3 shows PanIN tissue, 
moderately differentiated tissue, and poorly differentiated PDAC pancreas tissue stained 
with 12. The selective accumulation in the ducts versus stroma is observed as the bright 
white spots (ducts with adenocarcinoma) and relatively dark regions (stroma tissue). 
 
 
Figure 3. Whole tissue images of frozen sections (top panel) of healthy, PanIN, poorly differentiated and 
moderately differentiated human normal and PDAC pancreas tissue stained with 12. In the bottom panel 
shows magnified images of healthy ducts (A) and PDAC (B- PanIN (lesions), C- poorly differentiated and 
D- moderately differentiated). 
 
 Staining protocol optimization using mouse tissue 
Since the results using human tissue were consistent with those obtained with the KMC 
mouse model, we utilized mouse frozen sections to optimize the staining procedure. Since 
H&E staining, the gold standard for FSA pathology, requires ca. 12 min to stain tissue, our 




optical contrast. In order to evaluate S/B (PDAC/stroma) during optimization, we 
employed a modified Matlab code used by Barth et al. (2017)18 to generate the area under 
a receiver operating characteristic (ROC) curves, with the AUC used as a metric of 
diagnostic performance in differentiating PDAC from stroma. For the KMC tissue used, 
the ROC curves, the AUC values are reported in Figure 4 and Table 1, respectively. The z-
stat analysis reported the 125 µM, 5 min incubation time AUC value as significantly higher 
than all other staining conditions (Table S1, supplementary information). 
 
 
Figure 4. ROC curves for KMC mouse model ductal adenocarcinoma vs. stroma tissue differentiation 








Table 1. Tissue staining optimization ROC analysis. AUC values are listed for fluorophore 
concentration and incubation time optimization studies with KMC mouse model tissue. 




1 min  5 min 10 min 40 min 
125 0.8541 0.9390 0.9143 0.8556 
250 0.7307 0.8337 0.8751 N/A 
500 0.8691 0.8695 0.8810 N/A 
  N/A- not applicable 
 aROC AUC values correspond to the area under the ROC curve for each incubation time 
with 12. 
 
The initial fluorophore concentration reported by Wang et al. (2017)9 of 125 µM 
afforded the highest AUC with a fluorophore incubation time of 5 min (Table 1). A short 
rinse instead of 5 min washing, plus a shortened incubation with 2% PFA 
(paraformaldehyde, 5 min compared to 15 min) did not significantly change the AUC 
(0.9390 vs. 0.9376 for original vs. optimized protocols). 
 
Figure 5. Signal quantification from PDAC KMC mouse model tissue represented as pixel intensity 
histograms. Unstained PDAC control tissue (left) and PDAC tissue stained with 12 (right) using the 
optimized protocol: 125 µM with 5 min incubation, rinse and 5 min PFA incubation (total 15 min). The 
separation of pixel values in stained tissue is evidence of its efficiency in selective PDAC targeting over 





Optimized protocol (15 min processing) results are represented in Figure 5. The 
histogram of PDAC pancreas tissue stained with 12 displays a clear resolution of pixel 
values between the ductal adenocarcinoma and the stroma tissue. This is evidence that 
when 12 is used in the 15-min protocol it is effective in selectively targeting and imaging 
PDAC. Conversely, a PDAC negative control was subjected to the same conditions except 
for the addition of 12.  It shows an unresolved pixel intensity overlay corresponding to 
PDAC and stroma (Figure 5, left).  
Once the procedure was optimized with mouse tissue, it was applied to human 
frozen section samples. The optimized protocol was used to stain the four human pancreas 
tissue samples shown in Figure 3 (the Figure 2 images had been obtained using 
unoptimized conditions), including healthy and pancreatic intraepithelial neoplasia (PanIN, 
a PDAC precursor lesion of potential utility for early disease detection), as well as 
moderately- and poorly-differentiated PDAC tissue. ROC-calculated AUC values were 






Figure 6. ROC curves for control (black), PanIN (green), high grade (brown) and low grade (red) human 
ductal adenocarcinoma vs. stroma tissue differentiation derived from staining with 12.  
 
Table 2. ROC AUC values for human tissue staining with compound 12. 
 
 
a60% exocrine epithelium, 20% endocrine 
epithelium, 20% ducts; bpancreatic intraepithelial 
neoplasia non-tumor structures with 10% exocrine 
epithelium, 5% endocrine epithelium, 85% ducts;  
ctumor grade G2 (moderately differentiated); dtumor 
grade G3 (poorly differentiated). 
 
Tissue type ROC AUC 
Healthya 0.4508 
PanINb 0.7797 
Moderately differentiatedc 0.8821 





The primary aim of this study was to show the utility of an inherently-targeted 
fluorophore in the ex vivo staining of human PDAC tissue. Residual tumor during PDAC 
resection results in low survival rates from PDAC surgery due to locoregional recurrence 
or follow-up surgeries to ensure clear margins. Intraoperative fluorescence guidance using 
PDAC-specific contrast agents has the potential to aid the process of margin assessment. 
Typically, fluorophores are conjugated to targeting ligands to increase specificity. Ex vivo 
staining with fluorophore-antibody conjugates takes between 24 and 48 hours to obtain an 
image, which is not practical for surgery. In the previous study, 12 was shown to achieve 
specificity to PDAC in a PDAC mouse model without the need for conjugation to an 
antibody or any complex targeting ligands. Herein, we have shown that it can be used for 
analyzing human PDAC frozen tissue sections following a short 15-min staining protocol. 
It exhibits enhanced accumulation in the ducts of the adenocarcinoma versus the 
surrounding stroma tissue. In addition, it stains PanIN precancerous lesions which may be 
useful for investigating the progression of PDAC. 
 
Unlike the current FSA stain (H&E), 12 affords quantifiable images and PDAC 
specificity. The fluorescence in pancreas tissue was quantified using ROC curves. The high 
contrast between the stroma and the adenocarcinoma in 12 stained tissue can serve as 
marker for PDAC. For example, it may enable margin assessment both qualitatively and 
quantitatively since stained healthy pancreas tissue does not show appreciable contrast 




frozen section staining using 12 under the optimized conditions described herein takes 
place in nearly the same amount of time as H&E staining. It is also promising that high 
contrast was also observed in the tissue sample containing the PanIN pancreatic cancer 




Table S1. Tissue staining optimization z-stat analysis. 




1 min  5 min 10 min 40 min 
125 264.4 N/A 74.1 248.6 
250 307.3 197.1 219.8 N/A 
500 167.5 130.3 112.1 N/A 
az-statistical values for each staining condition and incubation time compared to the 125µM, 5 min 





Figure S1. Whole tissue images (in triplicate) of frozen sections (from top) of healthy, PanIN, poorly 
moderately differentiated and moderately differentiated human normal and PDAC pancreas tissue stained 







Figure S2. Whole tissue images of frozen sections from KMC mouse PDAC pancreas tissue stained with 
different concentrations of 12 for different incubation times and unstained PDAC control tissue as the first 
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ABSTRACT 
Fluorescent small molecules enable researchers and clinicians to visualize 
biological events in living cells, tissues, and organs in real time. Herein, the focus is on the 
structure and properties of the relatively rare benzo[a]xanthenes that exhibit enhanced 
steric and electronic interactions due to their annulated structures. Three types of 
fluorophores were synthesized: (i) pH and solvent dependent seminaphthorhodafluors, (ii) 
pH and solvent independent seminaphthorhodafluors, and (iii) pH-independent but solvent 
sensitive seminaphthorhodamines. The probes exhibited promising far-red to near-infrared 
(NIR) emission, large Stokes shift, broad full width at half maximum (FWHM), relatively 
high quantum yields, utility in PDAC imaging and immunofluorescence staining. 
Deviation of the π-system from planarity due to changes in the fluorophore ionization state 
resulted in fluorescence properties that are atypical of common xanthene dyes. 
INTRODUCTION 
Xanthenes, including benzoxanthene derivatives (Figure 1), are of considerable 
interest in chemical biology. They are an important class of heterocyclic compounds in 
both photophysical and medicinal chemistry.1-6 Benzoxanthenes have been employed as 
fluorescent materials for the recognition of biologically important molecules.7,8 Their light 




attention has been paid to the structural design and modification of benzoxanthenes due to 
their attractive biological and antiproliferative properties.10-12 We have previously reported 
a family of water-soluble, low molecular weight, NIR-emitting seminaphthofluorones 
wherein modifications to the regiochemistry of the ionizable groups and annulation 
directions have led to significant modulation of spectral properties.13 Transposition of the 
ionizable moieties, as a design variable of benzo[c]xanthene analogs, resulted in unusually 
large Stokes shift (~200 nm) and emissions in the NIR (> 750 nm).14,15 In our previous 
work, a seminaphthorhodafluor dye featured an inherent affinity for pancreatic ductal 
adenocarcinoma (PDAC) cells without the need for conjugation to any targeting agents.16  
This was accomplished through a systematic modification of three classes of 
benzo[c]xanthene fluorophores with an emphasis on pharmacochemical properties. The 
study described herein focuses on a series of red-to-NIR emitting fluorescent 
benzo[a]xanthene annulated probes containing various polar groups (Y, on C-5, Figure 1), 
including their synthesis, spectral properties, computational modeling and in vitro imaging. 
 
Figure 1. Annulation of the xanthene chromophore can lead to three types of benzoxanthenes. The 





The design of a library of nine fluorophores was based on systematic functional 
group variation (Figure 2).  At C-5, the hydroxyl, methoxy or amine functionality, as well 
as different levels of rigidity at the C-10 iminium group were varied. All structures possess 
a methyl benzoate at C-7, allowing for eventual conjugation to biological molecules. 
Compounds 1, 4 and 7 are the only pH- and solvent-dependent fluorophores in the series. 
Substitution of the hydroxyl at C-5 with a methoxy group results in analogs 2, 5, and 8. 
The corresponding naphthylamine are compounds 3, 6, and 9. 
 
Figure 2. Seminaphthorhodafluors and seminaphthorhodamines. 
RESULTS AND DISCUSSION 
Fluorophore synthesis and characterization. Seminaphthorhodafluor analogs 
(Figure 2) were synthesized in three steps (Scheme 1). Briefly, condensation of the 
corresponding hydroxybenzophenone with the appropriate 2-naphthol derivative in a 
mixture of CH3SO3H:TFA (1:1) at 80 °C for 16-24 h produced a single isomer 
(benzoxanthene type a) as the major product.  Single-crystal X-ray structure analysis and 
2D NMR (COSY), confirmed the structure assignment. Subsequent Fischer esterification 
to produce the methyl ester derivatives was carried out under reflux conditions in 
anhydrous MeOH and catalyzed by HCl. The required starting materials 2-(2,4-




hydroxy-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carbonyl)benzoic acid, and 
2,7-naphthalene derivatives were synthesized according to published literature 
protocols.10,16,17 In the case of the seminaphthorhodamines (Figure 2), we followed a 
protocol developed recently by our group.18 All compounds were isolated by flash column 
chromatography on silica gel, preparative TLC or reversed phase chromatography, and 
characterized by 1D and 2D NMR as well as HR-ESI-MS. Detailed characterization data 
and procedures are described in the experimental section. 






Spectroscopic studies of the pH-dependent seminaphthorhodafluors. The 
products were screened for pH and solvent dependence, relative quantum yields are 
reported as the average of multiple measurements using multiple references (Appendix 
A).19 Their optical properties in MeOH are summarized in Table 1. The absorption and 
emission spectra of all fluorophores included in this series display broad, structured peaks, 
which enables efficient use over a wide range of wavelengths. All exhibit broad FWHM 
ranges from 101 to 182 nm, covering a significant window of the NIR region (Figure 3). 
Stokes shifts range from 40 to 100 nm. 












 (nm) (nm) (nm) (M -1·cm -1) (%)  (nm) 
1 527 630 103 29,276 4.6 1347 151 
2 520 590 70 26,261 41.99 11027 132 
3 568 610 42 18,013 1.08 195 182 
4 556 610 54 28,896 3.97 1147 110 
5 520 610 90 27,549 11.65 3210 114 
6 584 640 56 26,110 0.68 178 114 
7 538 630 92 25,562 20.52 5245 114 
8 535 630 95 26,275 18.36 4824 116 
9 592 670 78 21,690 1.6 347 148 
 
At low pH, 1, 4 and 7 are red-to-NIR emitting (Figure 3). Their absorption spectra 
display structured peaks with maxima ranging from 520 to 540 nm, large Stokes shifts (60 
- 92 nm), and emission maxima between 580 and 630 nm The absorption and fluorescence 




over the physiological range, as well as sensitivity to other solvent systems (MeOH, 
DMSO).  In aqueous solution, ratiometric absorption spectra with well-defined isosbestic 
points are observed (Figure 4a). At high pH, the neutral forms (deprotonated naphthols) 
display red-shifted absorption peaks at ca. 600 nm. Surprisingly, as the pH of the aqueous 
solutions of 1, 4 and 7 is increased further, the fluorescence intensity decreases to a non-
fluorescent state (pH =12.1, Figure 4g). Overall, the pKa values range from 8.07 for 
compound 1 to 8.39 for compound 7, embodying enhanced acidity as compared to 2-
naphthol (pKa = 9.51). Although small differences in pKa for rhodols 1, 4 and 7 are 
observed, they follow the expected trend associated with N-substitution at C-10 (7>4>1). 
Solvent dependence can be at least partially attributed to the differences in the equilibria 
of the tautomers of the compounds. In organic solvents, absorptions from each tautomer 
are observed, with the shorter wavelength species predominating, similar to what is 
observed in the neutral buffer (Figure 4d). Quantum yields are generally about 3-27 times 






Figure 3.  Spectral properties of compounds 1−9 in aqueous media. To ensure the cationic form, compounds 
1, 4 and 7 were dissolved in pH 1.9 aqueous solution with the remaining compounds dissolved in pH 7.4 
solution. (a) Absorption spectra (solid lines) and normalized fluorescence emission spectra (dash lines) of 
pH-dependent seminaphthorhodafluors (1, 4, and 7) in acidic solution 1:9 DMSO:HCl (12.5 mM in H2O, pH 
1.9) shows a red-shifted lmax and emission maximum for 7, which embody the extra ring system for rigidity 
(540 nm and 630 nm respectively) compared to 1 and 4. (b) pH-independent seminaphthorhodafluors (2, 5, 
and 8) in 1:9 DMSO:buffer (12.5 mM phosphate, pH 7.4) shows analogous absorption spectra of 2, 5 and 8 
compared to 1, 4 and 7 with the emission spectra of 2, 5 and 8 all in the red-to-NIR region. (c) pH-independent 
seminaphthorhodamines (3, 6, and 9) in 1:9 DMSO:buffer (12.5 mM phosphate, pH 7.4) shows comparable 
lmax and emission spectra between 6 and 9, with 6 showing high peak intensity for both absorption and 
emission spectra. Compound 3 absorption and emission spectra is blue-shifted, compared to 6 and 9.   
Emission spectra are normalized to their corresponding absorption peaks. Excitation Emission Matrices 
(EEMs) are provided in the Appendix A. 
 
Spectroscopic studies of pH-independent seminaphthorhodafluor methyl 




and 8) eliminates both pH and solvent dependence (Figure 4b, and 4e). At pH 7.4, 
compounds 2, 5, and 8 exist as single species, similar to what is observed for 1, 4 and 7 in 
acidic solution. Absorption spectra are nearly identical to the corresponding hydroxyl 
analogs. The emission wavelengths of the methyl ethers are also in the red-to-NIR region, 
(Figure 4g), including large Stokes shifts (90-105 nm). Quantum yields, ranging from about 
12-42%, are higher compared to 1, 4 and 7 (~ 64-fold higher for compound 2). No spectral 
evidence for tautomeric equilibria is observed for the methyl ethers, with the absorption 
spectrum of compound 8 being the most stable over the pH range from 1.9 to 12.1 (Figure 
4b), followed by compound 5, then 2 (SI). There is negligible change in the absorption 
spectrum upon changing solvents from DMSO to MeOH to neutral pH buffer (Figure 4e).  
Spectroscopic studies of pH-independent seminaphthorhodamines. 
Seminaphthorhodamines 3, 6 and 9 are pH-insensitive, but exhibit greater solvent-
dependent spectral changes compared to seminaphthorhodafluors 1, 4, and 7. Compound 
9 shows the highest stability over the pH range of 1.9 to 12.1 (Figure 4c), followed by 6, 
then 3 (SI). Their emission maxima range is from 610 to 670 nm, with broad FWHM of up 
to 182 nm (in MeOH), covering a significant portion of the NIR region. Stokes shifts range 
from 50 to 105 nm in aqueous media. Quantum yields are generally two times higher in 
MeOH compared to neutral buffer. Solvatochromic behavior (up to 60 nm) is observed for 
the longest wavelengths in DMSO and for the shortest in aqueous media (Figure 4f).  
Molecular simulations. Density functional theory (DFT) calculations were 
performed to further investigate the relationship between the structural and electronic 




and the lowest unoccupied molecular orbitals (LUMOs) were obtained from the optimized 
molecular geometries in the ground state at the B3LYP/6-31+G(d,p) level of theory using 
Gaussian 09 (see Table 2).20  Notably, electrons are preferentially localized on the naphthyl 
annulation region of the molecule within the HOMO, and more delocalized over the 
xanthene dye core of the molecule in the LUMO (Figure A9, Appendix A). 
 
Table 2.  Dihedral angles (C(7-10)) and dipole moment for compounds 7, 8 and 9 in their 
cationic and neutral forms from DFT-optimized geometries in the ground state. 
Compound dihedral angle 
(ϕ, º) C(7-10) 
dipole moment  
(µ, Debye) 
 cation neutral cation neutral 
7 -1.4 -11.2 3.1 11.6 
8 -3.1 N/Aa 7.5 N/Aa 
9 -0.2 -12.4 2.7 7.8 
          aNot applicable. The neutral form cannot be produced. 
To understand the effects of pH on the emission (as shown in Figure 4g) of 
compounds 7, 8, and 9 at the molecular level, we further examined geometries and 
electronic properties. DFT calculations revealed a distortion of the conjugated π-systems 
from planarity for the neutral forms of 7 and 9 (Figure 5). The dihedral angles (C7-10) are > 
-11° (Table 2). In contrast, the dihedral angles in the cationic forms are closer to 0°, 
consistent with the more typical planar conformation. Similarly, compound 8, which exists 




relationships are observed for the other two pH-dependent fluorohores, 1 and 4 (Table A11, 
Appendix A), wherein the neutral molecules exhibit greater dihedral angles compared to 
the corresponding cations.  
It is not surprising that pH-insensitive methoxy-functionalized 8 affords relatively 
consistent emission over the entire pH range studied. However, the emission from naphthol 
7 is dim at pH ca. 9 and above as shown in the EEMs (Figure 4g). This is not typical for 
xanthenes such as fluorescein or even the type[c] benzoxanthenes, wherein higher pH 
enhances and red-shifts fluorescence emission.21 This unique effect is ascribed to the 
aforementioned increased dihedral angle distortion in the neutral form of 7 (pKa = 8.39 ± 
0.06).  
Since the neutral and cationic forms of amino analog 9 have very similar dihedral 
angles compared to neutral and cationic 7, compound 9 should exhibit enhanced 
fluorescence at low pH levels, for instance at levels below the pKa of an ammonium cation. 
However, rhodamine and congeners are well-known to be relatively pH-insensitive, and to 
display relatively bright emission over broad pH ranges. In the case of 9, however, the 
EEMs in Figure 4g show relatively bright fluorescence at only the lowest solution pH 
studied (1.9). The emission diminishes sharply as the equilibrium shifts towards the neutral 
form at higher pH values. This is in keeping with the emissive properties of neutral versus 
cationic 7, and serves as further evidence that fluorescence modulation in 
benzo[a]xanthenes is related to increases in the dihedral angle formed by carbons 7-10 





Figure 4. Comparison of the optical properties of compounds 7-9. (a) Absorption spectra of 7 (pH-sensitive) 
as a function of pH shows that above pH 9, 7 is red shifted and shows an isosbestic point ca. 550 nm across 
the pH range studied. (d) Absorption spectra of 7 as a function of solvents including DMSO, MeOH, and 1:9 
DMSO:buffer (12.5 mM phosphate, pH 7.4) shows minimal solvent dependence. In DMSO absorption of 
tautomer is observed ca. 750 nm. (b) Absorption spectra of 8 (pH-insensitive) as a function of pH shows an 
overlay of absorption spectra across the pH range studied confirming the expected pH independence of 8. (e) 
Absorption spectra of 8 as a function of solvents shows minimal solvent dependence. (c) Absorption spectra 
of 9 (pH-insensitive) as a function of pH shows minimal pH dependency across the pH range studied. (e) 




hydrogen bonding between solvent and -NH2 on 9 versus -OH on 7. Inset figures are ambient light 
photographs of the compounds in solution. (g) Normalized excitation emission matrices (EEMs) as a function 
of pH for compounds 7, 8, and 9. Fluorescence intensity of 7 reduced at pH 9 and diminishes completely at 
pH 12 due to twisting in the chromophore from the deprotonation of -OH (pKa ~ 8.4). Fluorescence intensity 
of pH insensitive 8 remain consistent across pH range studied. Fluorescence intensity of 9 diminishes after 
pH 6 due to the equilibria formed between cationic 9 and deprotonated -NH2 neutral 9 with twisted 





Our calculations also show an increased charge separation in the neutral 7 and 9, 
with dipole moment values 3-4 times higher compared to the cationic forms (Table 2).  
Molecular electrostatic potential surfaces calculations using the natural bound order (NBO) 
display a significant charge repulsion between the centroid of the benzoate ring and the 
heteroatom at the edge of the [a] annulated ring system (Figure 6). The result of the charge 
repulsion of the naphthyl moiety is an increase in the dihedral angle formed by C7-C10. 
 
Figure 5. DFT-optimized geometries of the cationic (top) and the neutral forms (bottom) of compounds 7 
(left) and 9 (right). The torsion in the naphthyl annulation region increases upon deprotonation of the 
hydroxyl and amino groups, respectively. The bond lengths in angstroms and dihedral angles (ϕ) for C7-C10 







Figure 6.  Calculated molecular electrostatic potential surfaces of DFT optimized geometries of the cationic 
and the neutral forms of compounds 7 and 9 in the ground-state. 
In vitro studies. To investigate their biocompatibility and utility in live cell 
imaging, compounds 1 through 9 were screened for cytotoxicity in Capan-1 cells (a human 
PDAC cell line) (Figure 7). Cell viability is reported as the half maximal inhibitory 
concentration (IC50) for each compound. Interestingly, methoxy analogs (2, 5, and 8) 
exhibited higher cytotoxicity as compared to their corresponding hydroxyl analogs (1, 4, 
and 7) and amine analogs (3, 6, and 9). Moreover, alkylation at the C-10 nitrogen seemed 
to result in increased cytotoxicity, with compound 1 the least toxic (IC50 30.96 µM), 
followed by compound 4 (IC50 26.30 µM), and then 7 (IC50 13.45 µM) among three pH-
dependent seminaphthorhodafluors. The same relationship was also observed for the other 
two sets of fluorophores, with IC50 value comparisons of 2>5>8 for pH-independent 
seminaphthorhodafluors, and 3>6>9 for the pH-independent seminaphthorhodamines. The 






Figure 7. Cell viability of compounds 1-9. Cytotoxicity was determined by Cell Titer-Blue assay. Capan-1 
cells were incubated with decreasing concentrations from 100 µM of each compound in growth media. The 
half maximal inhibitory concentrations (IC50) determined by interpolating values in the graph (% cell viability 
vs fluorophore concentration). 
The subcellular localization (Figure 8) of compound 8 was investigated in Capan-
1 cells. Organelle-specific fluorescent probes for the nucleus (DAPI), endoplasmic 
reticulum (ER), lysosomes (Lyso), and mitochondria (Mito) were used to assess the site-


























































limited accumulation in the nucleus, endoplasmic reticulum, and mitochondria, showing 
utility as a cell membrane permeable fluorescent probe for live cell imaging. 
 
Figure 8. Subcellular localization of compound 8. Images of subcellular organelles stained with commercial 
fluorescent trackers are labeled as DAPI (blue), Lyso (green), Mito (green), ER (green). Mid-column shows 
the images of cells stained with compound 8 (red). The merge column shows images of (top) colocalization 
of DAPI + 8, followed successively below by, colocalization of Lyso + 8, colocalization of Mito + 8, and 
colocalization of ER + 8. 
Compound 8 was used in the staining of a human PDAC tissue specimen, purchased 
from Origene, Inc. The goal was to compare the staining pattern of 8 to that of compound 
12 from the benzo[c]xanthene library (Chapter 2). The physicochemical properties of 8 are 
close to those of 12, with the dipole moment of 8 an exception, nearly 2x that of 12 (Figure 
9). Utilizing the area under the curve (AUC) as a measure of effective PDAC targeting, 8 
displayed an AUC slightly < that of 12, but still high (AUC > 0.5). This shows that 
maintaining physicochemical properties in the novel benzo[a]xanthene probes can preserve 















Figure 9. A direct comparison of the human PDAC tissue staining pattern of 8 (benzo[a]xanthene) and 12 
(benzo[c]xanthene). 
 
Since compound 8 exhibits a large Stokes shift, broad FWHM, appreciable 
brightness, and high stability across organic and aqueous buffer solutions, it was modified 
to produce the NHS activated probe 8-NHS (Scheme 2). Compound 8-NHS was conjugated 
to bovine alpha-tubulin mouse antibody as the primary and donkey anti-mouse antibody as 
the secondary antibody. The fluorophore to antibody-labeling conjugation ratio was 2.8:1, 
as determined by UV-Vis analysis. Immunoconjugates were used for indirect 
immunofluorescence staining in fixed U2OS cells at a 200 nM concentration. Figure 10 
shows high contrast and detailed microtubular network visualization, demonstrating 














Figure 10. Immunofluorescence imaging of a microtubule network. Tubulin was labeled using indirect 
immunofluorescence with compound 8-NHS in fixed U2OS cell at 200 nM concentration (left); negative 
control fluorescence image of fixed U2OS cells incubated with donkey, anti-mouse secondary antibody (pre-
conjugated with compound 8-NHS) only (right). Scale bar 100 µm. 
CONCLUSION 
In summary, an efficient synthesis of red-to-NIR benzo[a]xanthene analogs has 
been developed. Spectral and physicochemical properties were tuned by varying the 
substituent at C-5 (-OH, -OMe or –NH2). These changes afforded three types of 





seminaphthorhodafluors, (ii) pH and solvent independent seminaphthorhodafluors and (iii) 
pH independent but solvent dependent seminaphthorhodamines. Fluorescence properties 
observed included far red-to-NIR emission, large Stokes shifts (103 nm at neutral pH), 
broad FWHM (182 nm in MeOH) and relatively high quantum yields (42% in MeOH). 
Minimal cytotoxicity and relatively bright fluorescence rendered the dyes suitable for live 
cell imaging, as well as site-specific immunofluorescence imaging applications. Changes 
to the C-5 substituent led to significant modulation of fluorescence emission as a function 
of ionization state. This was ascribed to deviations from planarity in the chromophore. 
This effect was associated with brighter fluorescence observed at lower solution pH 
values, which is opposite the trend typically exhibited by other xanthene and 
benzoxanthene dyes. The type [a] annulated fluorophores thus add architectural diversity 
and complementary fluorescent properties to the common xanthene dyes. Since they are 
analogs of the type [c] benzoxanthenes that have previously exhibited inherent cancer 
tissue targeting,16 the type [a] fluorophores enabled PDAC imaging providing insights into 
how structural changes modulate not only the optical but also the targeting and biological 
properties of the benzoxanthenes.  
 
METHODS 
General. Unless otherwise indicated, all commercially available starting materials 
were used directly without further purification. Silica gel Sorbent Technologies 32-63 µm 




Advance Bruker spectrometer. Chemical shifts (d) are given in ppm relative to DMSO-d6 
(2.50 ppm, 1H, 39.52 13C) unless otherwise indicated.  MS (HRMS, ESI) spectra were 
obtained at the PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron LTQ-
Orbitrap high resolution mass spectrometer with a dedicated Accela HPLC system, or an 
Agilent 6244 time-of-flight LCMS with diode array detector VL+. 
 Synthesis of 2-(4-amino-2-hydroxybenzoyl)benzoic acid (11). Rhodamine 110 
hydrochloride (1 g, 2.725 mmol) is mixed with NaOH (1.875 g, 4.635 mol) and 1 mL of 
water. The mixture is stirred and heated in an oil bath at 160 oC for two hours, 3 mL of 
50% NaOH are added in one portion and the mixture heated and stirred at 160 oC for an 
additional one hour. The mixture is allowed to cool down to rt and diluted with 50 mL of 
water. The mixture is acidified to pH 1 with concentrated HCl. The resulting mixture is 
extracted with ethyl ether (2 × 50 mL), the organic extracts combined, dried over anhydrous 
Na2SO4, filtered and the solvent evaporated under reduced pressure to leave a pale yellow 
solid.  Yield 0.61 g, 87 %. 1H NMR (400 MHz, DMSO-d6) δ 13.01 (s, 1H), 12.60 (s, 1H), 
7.95 (dd, J = 7.8, 1.2 Hz, 1H), 7.67 (td, J = 7.5, 1.4 Hz, 1H), 7.60 (td, J = 7.6, 1.4 Hz, 1H), 
7.37 (dd, J = 7.6, 1.2 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 6.44 (s, 2H), 6.04 – 5.97 (m, 2H). 
13C{1H} NMR (101 MHz, DMSO-d6) δ 198.3, 166.9, 165.0, 156.8, 140.1, 134.5, 132.0, 
129.9, 129.7, 129.3, 127.7, 109.8, 106.5, 106.2, 98.2, 48.6. HRMS (ESI-Orbitrap) m/z: [M 
- H] - Calcd for C14H10NO4 256.0615; Found 256.0627. 
Synthesis of 2-(4-(dimethylamino)-2-hydroxybenzoyl)benzoic acid (20). Compound 




mmol) are dissolved in 30 mL of toluene and refluxed with an oil bath for 12 h. The solvent 
is evaporated under vacuum to leave a purple residue. The residue is dissolved in ethyl 
acetate and the mixture passed through a plug of silica gel using EtOAc:Hexanes 1:1, 
EtOAc:Hexanes 3:1, and EtOAc for elution. Yield 4.32 g, 42%. 1H NMR (400 MHz, 
DMSO-d6) δ 13.07 (s, 1H), 12.54 (s, 1H), 7.97 (dd, J = 7.8, 1.2 Hz, 1H), 7.69 (td, J = 7.5, 
1.4 Hz, 1H), 7.61 (td, J = 7.6, 1.4 Hz, 1H), 7.38 (dd, J = 7.6, 1.1 Hz, 1H), 6.81 (d, J = 9.1 
Hz, 1H), 6.21 (dd, J = 9.2, 2.5 Hz, 1H), 6.10 (d, J = 2.5 Hz, 1H), 3.00 (s, 6H). 13C{1H} 
NMR (101 MHz, DMSO-d6) δ 198.7, 166.9, 164.3, 155.7, 140.0, 133.9, 132.1, 129.9, 
129.7, 129.5, 127.6, 109.7, 104.3, 97.0, 39.6. HRMS (ESI-Orbitrap) m/z: [M - H] - Calcd 
for C16H14NO4 284.0928; Found 284.0938. 
Synthesis of 2-(8-hydroxy-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-
carbonyl)benzoic acid (25). Phthalic anhydride (0.392 g 2.64 mmol) and 8-
hydroxyjulolidine (0.5 g, 2.64 mmol) are dissolved in 12 mL of toluene. The mixture is 
refluxed in an oil bath for 24 h, then the solvent evaporated under vacuum to leave a deep 
red residue.  The target compound is isolated as a pale yellow solid by flash column 
chromatography on silica gel using CH2Cl2:MeOH 95:5 for elution. Yield: 622 mg, 70%. 
1H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 2H), 7.94 (dd, J = 7.8, 1.3 Hz, 1H), 7.66 (td, J 
= 7.5, 1.4 Hz, 1H), 7.58 (td, J = 7.6, 1.4 Hz, 1H), 7.33 (dd, J = 7.5, 1.3 Hz, 1H), 6.39 (s, 
1H), 3.27 – 3.19 (m, 4H), 2.59 (t, J = 6.4 Hz, 2H), 2.40 (t, J = 6.2 Hz, 2H), 1.90 – 1.80 (m, 
2H), 1.80 – 1.70 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 197.9, 167.0, 159.7, 




21.1, 20.1, 19.5. HRMS (ESI-Orbitrap) m/z: [M + H] + Calcd for C20H20NO4 338.1387; 
found 338.1391; [M + Na]+ Calcd for C20H19NO4Na 360.1206; Found 360.1210. 
Synthesis of 7-methoxynaphthalen-2-ol (13). 2,7-naphthalenediol (1 g, 6.24 mmol, 1.0 
equiv) was dissolved in dry THF (14 mL) and cooled to 0 °C. NaH (60% dispersion in 
mineral oil, 250 mg , 6.24 mmol, 1.0 equiv) was added portion-wise and the reaction 
contents were stirred at 0 °C for 10 min; Me2SO4 (886 µL, 6.24 mmol, 1.0 equiv) was then 
added dropwise at 0 °C. The reaction contents were stirred for 14 h with slow warming 
from 0 °C to 25 °C. Upon completion, the contents were quenched by the addition of 
saturated NH4Cl (50 mL). They were then poured into water (50 mL) and extracted with 
EtOAc (3 × 50 mL). The combined organic extracts were washed with water (50 mL) and 
brine (50 mL), dried (MgSO4), and concentrated. The resultant crude grey solid was 
purified by flash column chromatography (silica gel. hexanes/Et2O, 2/1). monomethylated 
product (334 mg. 30%) as a purple solid. Rf = 0.32 (silica gel, hexanes/EtOAc, 2/1); 1H 
NMR (400 MHz, DMSO-d6) δ 9.63 (s, 1H), 7.64 (dd, J = 8.7, 2.7 Hz, 2H), 7.07 (d, J = 2.6 
Hz, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.94 – 6.85 (m, 2H), 3.83 (s, 3H). 13C{1H} NMR (101 
MHz, DMSO-d6) δ 157.6, 155.8, 136.0, 129.0, 129.0, 123.1, 115.9, 115.1, 108.1, 104.5, 
55.0. HRMS (ESI-TOF) m/z: [M + H] + Calcd for C11H11O2 175.0754; Found 175.0731. 
Synthesis of 7-aminonaphthalen-2-ol (14).17 2,7-dihydroxy naphthalene (5 g, 31.22 
mmol), formamide (1.37 mL, 34.34 mmol), and sodium sulfite (8.26 g, 65.56 mmol) are 
suspended in 50 mL of DI water. The reaction mixture is refluxed in an oil bath overnight. 




collected solid is dissolved in 100 mL of diethyl ether, and washed with 100 mL of 6 N 
HCl. The aqueous layer is basified to pH 13 with 50% NaOH solution, and washed with 
100 mL of diethyl ether. The aqueous layer is then neutralized to pH 7 with 2N HCl 
solution, and extracted with ethyl acetate (3 x 100 mL). The organic extract is combined, 
dried over anhydrous Na2SO4, and the solvent evaporated under vacuum. Yield: 3.02 g, 
61%. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 
8.8 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 6.67 (dd, J = 8.9, 2.1 Hz, 1H), 6.65 (dd, J = 9.0, 2.2 
Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 5.20 (s, 2H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 
155.4, 146.8, 136.6, 128.9, 128.3, 121.2, 115.2, 113.4, 106.3, 104.6. HRMS (ESI-Orbitrap) 
m/z: [M + H] + Calcd for C10H10NO 160.0757; Found 160.0755. 
General condensation procedure.  Hydroxybenzophenone (0.918 mol) and 1,8-
naphthalene derivative (1.380 mol) are dissolved in 1.5 mL of methanesulfonic acid, then 
1.5 mL of TFA are added. The mixture is heated and stirred in an oil bath at 80 oC for 16-
24 h.  The reaction mixture is allowed to warm to rt, then poured into 50 mL of DI water. 
If no precipitate is formed, the mixture is neutralized to pH 6-7 by portion wise addition of 
solid NaHCO3. The resulting precipitate is filtered, washed with DI water and air dried.  
The target compound isolated by flash column chromatography on silica gel, preparative 
TLC or medium pressure reversed chromatography as required. 
General esterification procedure.  Under Ar atm, compound (0.131 mmol) is dissolved 
in 25 mL of anhydrous MeOH. The solution is cooled to 0 oC in an ice bath.  Acetyl chloride 




chloride (300 µL) is added dropwise and the mixture kept at 50 oC for additional 24 h.  The 
mixture is allowed to cool down to rt and the solvent is evaporated under vacuum. 
Synthesis of 9-amino-2-hydroxy-3'H-spiro[benzo[a]xanthene-12,1'-isobenzofuran]-
3'-one (15). Following general condensation method, compound 11(100 mg, 0.389 mmol) 
and 12 (62.3 mg, 0.389mmol) were condensed to provide compound 15, yield 93 mg, 63%. 
1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 8.13 – 8.06 (m, 1H), 7.94 (d, J = 8.9 Hz, 
1H), 7.75 (d, J = 8.7 Hz, 1H), 7.72 – 7.63 (m, 2H), 7.26 (d, J = 8.9 Hz, 1H), 7.16 – 7.10 
(m, 1H), 6.90 (dd, J = 8.7, 2.3 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 6.34 (dd, J = 8.7, 2.3 Hz, 
1H), 6.25 (d, J = 8.7 Hz, 1H), 6.22 (d, J = 2.2 Hz, 1H), 5.62 (s, 2H). 13C{1H} NMR (101 
MHz, DMSO-d6) δ 169.4, 156.4, 154.6, 150.9, 150.7, 149.8, 135.7, 132.8, 132.5, 130.9, 
129.7, 127.7, 126.4, 125.3, 125.0, 123.2, 116.1, 114.6, 111.7, 106.6, 106.5, 106.4, 98.4, 
83.9. HRMS (ESI-Orbitrap) m/z: [M + H] + Calcd for C24H16NO4 382.1074; Found 
382.1068. 
Synthesis of 9-amino-2-methoxy-3'H-spiro[benzo[a]xanthene-12,1'-isobenzofuran]-
3'-one (16). Following general condensation method, compound 11(100 mg, 0.389 mmol) 
and 13 (67.7 mg, 0.389 mmol) were condensed to provide compound 16, yield 93 mg, 61%. 
1H NMR (400 MHz, DMSO-d6) δ 8.20 – 8.10 (m, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.86 (d, J 
= 8.9 Hz, 1H), 7.77 – 7.70 (m, 2H), 7.37 (d, J = 8.9 Hz, 1H), 7.27 – 7.20 (m, 1H), 7.00 (dd, 
J = 8.9, 2.4 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 6.37 (dd, J = 8.7, 2.1 Hz, 1H), 6.33 (d, J = 
8.7 Hz, 1H), 6.27 (d, J = 2.4 Hz, 1H), 5.67 (s, 2H), 3.26 (s, 3H). 13C{1H} NMR (101 MHz, 




127.9, 126.6, 125.9, 124.9, 123.7, 115.9, 115.8, 111.8, 107.2, 105.9, 103.1, 98.5, 84.2, 54.5. 
HRMS (ESI-Orbitrap) m/z: [M + H] + Calcd for C25H18NO4 396.1230; Found 396.1228. 
Synthesis of 9-(dimethylamino)-2-hydroxy-3'H-spiro[benzo[a]xanthene-12,1'-
isobenzofuran]-3'-one (21). Following general condensation method, compound 20 (100 
mg. 0.350 mmol) and 12 (56.1 mg, 0.350 mmol) were condensed to provide compound 21, 
yield 67 mg, 45%. 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.14 – 8.09 (m, 1H), 
7.96 (d, J = 8.7 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.73 – 7.64 (m, 2H), 7.27 (d, J = 8.9 Hz, 
1H), 7.16 – 7.10 (m, 1H), 6.91 (dd, J = 8.8, 2.2 Hz, 1H), 6.56 – 6.50 (m, 2H), 6.39 (d, J = 
8.8 Hz, 1H), 6.25 (d, J = 2.2 Hz, 1H), 2.93 (s, 6H). 13C{1H} NMR (101 MHz, DMSO-d6) 
δ 169.4, 156.39, 154.6, 151.4, 150.9, 149.7, 135.7, 132.7, 132.6, 130.9, 129.7, 127.5, 126.3, 
125.3, 125.1, 123.2, 116.1, 114.5, 109.8, 106.71, 106.6, 106.4, 97.4, 83.6, 79.2. HRMS 
(ESI-Orbitrap) m/z: [M + H] + Calcd for C26H20NO4 410.1387; Found 410.1386. 
Synthesis of 9-(dimethylamino)-2-methoxy-3'H-spiro[benzo[a]xanthene-12,1'-
isobenzofuran]-3'-one (22). Following general condensation method, compound 20 (100 
mg, 0.350 mmol) and 13 (61.0 mg, 0.350 mmol) were condensed to provide compound 22, 
yield 104 mg, 70%. 1H NMR (400 MHz, DMSO-d6) δ 8.21 – 8.13 (m, 1H), 8.05 (d, J = 8.7 
Hz, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.76 – 7.71 (m, 2H), 7.38 (d, J = 8.9 Hz, 1H), 7.26 – 
7.20 (m, 1H), 7.01 (dd, J = 8.9, 2.4 Hz, 1H), 6.58 – 6.53 (m, 2H), 6.47 (d, J = 8.2 Hz, 1H), 
6.29 (d, J = 2.4 Hz, 1H), 3.28 (s, 3H), 2.94 (s, 6H). 13C{1H} NMR (101 MHz, DMSO-d6) 




125.9, 124.9, 123.7, 115.9, 115.7, 109.9, 107.2, 106.2, 103.1, 97.4, 83.9, 54.49, 39.8. 
HRMS (ESI-Orbitrap) m/z: [M + H] + Calcd for C27H22NO4 424.1543; Found 424.1542. 
Synthesis of 11-hydroxy-1,2,3,5,6,7-hexahydro-3'H-spiro[benzo[5,6]chromeno[2,3-
f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-3'-one (26). Following general 
condensation method, compound 25 (100 mg, 0.296 mmol) and 12 (47.5 mg, 0.296 mmol) 
were condensed to provide compound 26, yield 39 mg, 29%. 1H NMR (400 MHz, DMSO-
d6) δ 9.71 (s, 1H), 8.11 – 8.06 (m, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 
7.71 – 7.61 (m, 2H), 7.28 (d, J = 8.9 Hz, 1H), 7.14 – 7.08 (m, 1H), 6.90 (dd, J = 8.7, 2.2 
Hz, 1H), 6.20 (d, J = 2.2 Hz, 1H), 5.91 (s, 1H), 3.16 (t, J = 5.6 Hz, 2H), 3.10 (ddd, J = 7.2, 
4.7, 3.0 Hz, 2H), 2.89 (t, J = 6.6 Hz, 2H), 2.58 – 2.34 (m, 2H), 1.99 – 1.88 (m, 2H), 1.82 – 
1.71 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 169.4, 156.3, 154.6, 150.9, 145.1, 
143.7, 135.6, 132.7, 132.4, 130.9, 129.7, 126.4, 125.3, 125.0, 123.3, 123.2, 117.9, 116.0, 
114.8, 106.7, 106.3, 105.8, 105.8, 84.3, 49.0, 48.6, 26.9, 21.2, 20.6, 20.5. HRMS (ESI-
Orbitrap) m/z: [M + H] + Calcd for C30H24NO4 462.1700; Found 462.1702. 
Synthesis of 11-methoxy-1,2,3,5,6,7-hexahydro-3'H-spiro[benzo[5,6]chromeno[2,3-
f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-3'-one (27). Following general 
condensation method, compound 25 (100 mg, 0.296 mmol) and 13 (51.6 mg, 0.296 mmol) 
were condensed to provide compound 27, yield 45 mg, 32%. 1H NMR (400 MHz, DMSO-
d6) δ 8.19 – 8.11 (m, 1H), 8.02 (d, J = 8.9 Hz, 1H), 7.85 (d, J = 8.9 Hz, 1H), 7.76 – 7.69 
(m, 2H), 7.39 (d, J = 8.9 Hz, 1H), 7.25 – 7.18 (m, 1H), 6.99 (dd, J = 8.8, 2.4 Hz, 1H), 6.26 




(t, J = 6.5 Hz, 2H), 2.59 – 2.36 (m, 2H), 2.01 – 1.90 (m, 2H), 1.83 – 1.70 (m, 2H). 13C{1H} 
NMR (101 MHz, DMSO-d6) δ 169.4, 157.8, 154.7, 151.1, 145.2, 143.8, 136.1, 132.4, 
132.2, 131.0, 130.0, 126.6, 125.8, 124.9, 123.7, 123.5, 118.1, 115.9, 115.8, 106.9, 105.9, 
105.3, 103.1, 84.6, 54.5, 49.0, 48.6, 26.9, 21.2, 20.5, 20.5. HRMS (ESI-Orbitrap) m/z: [M 
+ H] + Calcd for C31H26NO4 476.1856; Found 476.1845. 
Synthesis of 2-hydroxy-12-(2-(methoxycarbonyl)phenyl)-9H-benzo[a]xanthen-9-
iminium (1). Compound 1 was prepared following general esterification method, yield 
92%. 1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.11 (d, J = 73.7 Hz, 2H), 8.55 – 
8.47 (m, 1H), 8.40 (dd, J = 7.2, 2.0 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 8.00 – 7.92 (m, 2H), 
7.81 (d, J = 8.9 Hz, 1H), 7.48 (dd, J = 6.9, 2.0 Hz, 1H), 7.23 (dd, J = 8.7, 2.0 Hz, 1H), 7.14 
(dd, J = 9.5, 2.0 Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H), 7.04 (d, J = 9.4 Hz, 1H), 6.31 (d, J = 
2.2 Hz, 1H), 3.56 (s, 3H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 165.1, 161.5, 160.7, 
158.9, 157.6, 156.7, 141.0, 137.1, 134.6, 132.4, 131.8, 131.7, 131.6, 130.8, 128.9, 128.4, 
125.2, 121.2, 117.9, 117.9, 114.8, 113.8, 109.9, 96.0, 52.5. HRMS (ESI-Orbitrap) m/z: [M] 
+ Calcd for C25H18NO4 396.1230; Found 396.1229. 
Synthesis of 2-methoxy-12-(2-(methoxycarbonyl)phenyl)-9H-benzo[a]xanthen-9-
iminium (2). Compound 2 was prepared following general esterification method, yield 
90%. 1H NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.18 (s, 1H), 8.59 (d, J = 9.0 Hz, 1H), 
8.42 (dd, J = 7.9, 1.3 Hz, 1H), 8.13 (d, J = 8.9 Hz, 1H), 8.05 (td, J = 7.6, 1.3 Hz, 1H), 7.94 
(dd, J = 8.3, 6.7 Hz, 2H), 7.58 (dd, J = 7.6, 1.2 Hz, 1H), 7.28 (dd, J = 8.8, 2.4 Hz, 1H), 7.17 




(s, 3H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 165.5, 162.3, 160.5, 160.2, 158.2, 156.8, 
140.8, 137.7, 135.3, 132.8, 132.4, 132.1, 131.6, 131.4, 129.7, 129.0, 126.6, 122.0, 118.9, 
118.3, 115.5, 115.4, 106.7, 96.6, 55.2, 53.1. HRMS (ESI-Orbitrap) m/z: [M] + Calcd for 
C26H20NO4 410.1387; Found 410.1395. 
Synthesis of N-(2-hydroxy-12-(2-(methoxycarbonyl)phenyl)-9H-benzo[a]xanthen-9-
ylidene)-N-methylmethanaminium (4). Compound 4 was prepared following general 
esterification method, yield 85%. 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.54 (d, 
J = 8.9 Hz, 1H), 8.45 – 8.35 (m, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.98 (td, J = 7.2, 1.6 Hz, 
2H), 7.78 (d, J = 8.9 Hz, 1H), 7.54 – 7.47 (m, 1H), 7.39 (dd, J = 9.8, 2.5 Hz, 1H), 7.27 (d, 
J = 2.5 Hz, 1H), 7.26 (dd, J = 9.2, 2.4 Hz, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.36 (d, J = 2.1 
Hz, 1H), 3.56 (s, 3H), 3.39 (s, 6H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 165.2, 160.6, 
159.0, 158.1, 157.0, 156.8, 141.3, 137.1, 134.6, 132.5, 131.7, 131.6, 130.9, 130.4, 128.9, 
128.4, 125.1, 118.9, 118.0, 117.6, 115.1, 113.6, 110.0, 95.6, 52.6, 41.4, 40.9. HRMS (ESI-
Orbitrap) m/z: [M] + Calcd for C27H22NO4 424.1543; Found 424.1547. 
Synthesis of N-(2-methoxy-12-(2-(methoxycarbonyl)phenyl)-9H-benzo[a]xanthen-9-
ylidene)-N-methylmethanaminium (5). Compound 5 was prepared following general 
esterification method, yield 95%. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 9.0 Hz, 
1H), 8.44 (dd, J = 8.0, 1.2 Hz, 1H), 8.15 (d, J = 8.9 Hz, 1H), 8.06 (td, J = 7.6, 1.3 Hz, 1H), 
7.95 (td, J = 7.7, 1.3 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.61 (dd, J = 7.8, 1.2 Hz, 1H), 7.43 
(dd, J = 9.8, 2.5 Hz, 1H), 7.31 (d, 2.4 Hz, 1H), 7.30 (dd, J = 8.8, 2.4 Hz, 1H), 7.05 (d, J = 




13C{1H} NMR (101 MHz, DMSO-d6) δ 165.1, 160.0, 159.8, 158.4, 156.9, 156.6, 140.6, 
137.2, 134.9, 132.4, 131.6, 131.1, 131.0, 130.6, 129.2, 128.6, 126.1, 119.3, 118.2, 117.9, 
115.2, 114.9, 106.3, 95.7, 54.7, 52.7, 41.5, 41.0. HRMS (ESI-Orbitrap) m/z: [M] + Calcd 
for C28H24NO4 438.1700; Found 438.1705. 
Synthesis of 11-hydroxy-9-(2-(methoxycarbonyl)phenyl)-1,2,3,5,6,7-
hexahydrobenzo[5,6]chromeno[2,3-f]pyrido[3,2,1-ij]quinolin-4-ium (7).  Compound 7 
was prepared following a general esterification method, yield 71 %. 1H NMR (400 MHz, 
DMSO-d6) δ 10.24 (s, 1H), 8.42 (d, J = 8.7 Hz, 1H), 8.40 – 8.34 (m, 1H), 7.98 (d, J = 5.9 
Hz, 1H), 7.97 – 7.91 (m, 2H), 7.80 (d, J = 8.9 Hz, 1H), 7.49 – 7.44 (m, 1H), 7.19 (dd, J = 
8.7, 2.3 Hz, 1H), 6.62 (s, 1H), 6.23 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 5.7 Hz, 2H), 3.62 (t, J 
= 5.9 Hz, 2H), 3.55 (s, 3H), 3.09 (t, J = 6.0 Hz, 2H), 2.70 (t, J = 6.5 Hz, 2H), 2.14 – 2.00 
(m, 2H), 1.93 – 1.81 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 165.1, 158.4, 157.0, 
155.7, 153.1, 151.4, 139.4, 137.3, 134.5, 132.2, 131.5, 130.7, 129.3, 128.7, 128.4, 125.3, 
125.2, 117.8, 117.7, 114.4, 113.8, 109.6, 104.1, 52.4, 51.1, 50.7, 27.0, 19.7, 18.9, 18.7. 
HRMS (ESI-Orbitrap) m/z: [M] + Calcd for C31H26NO4 476.1856; Found 476.1846. 
Synthesis of 11-methoxy-9-(2-(methoxycarbonyl)phenyl)-1,2,3,5,6,7-
hexahydrobenzo[5,6]chromeno[2,3-f]pyrido[3,2,1-ij]quinolin-4-ium (8). Compound 8 
was prepared following general esterification method, yield 81%. 1H NMR (400 MHz, 
DMSO-d6) δ 8.50 (d, J = 8.9 Hz, 1H), 8.41 (dd, J = 7.9, 1.0 Hz, 1H), 8.09 (d, J = 8.9 Hz, 
1H), 8.06 – 8.00 (m, 1H), 7.96 – 7.88 (m, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.57 (dd, J = 7.6, 




2H), 3.64 (s, 2H), 3.55 (s, 3H), 3.24 (s, 3H), 3.10 (d, J = 5.9 Hz, 2H), 2.71 (s, 2H), 2.14 – 
2.01 (m, 2H), 1.96 – 1.82 (m, 2H). 13C{1H} NMR (101 MHz, DMSO-d6) δ 165.0, 159.4, 
156.3, 155.4, 153.4, 151.4, 138.9, 137.5, 134.7, 132.1, 131.6, 131.0, 130.8, 129.6, 129.06, 
128.7, 126.1, 125.4, 118.3, 117.6, 115.1, 114.6, 105.9, 104.3, 54.7, 52.6, 51.3, 50.8, 27.0, 
19.7, 18.9, 18.7. HRMS (ESI-Orbitrap) m/z: [M] + Calcd for C32H28NO4 490.2013; Found 
490.2005. 
Compounds 3, 6, and 9 were synthesized according to a previous published protocol.18 
Synthesis of isomers 4-(8-hydroxy-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-
ij]quinoline-9-carbonyl)isophthalic acid and 2-(8-hydroxy-2,3,6,7-tetrahydro-1H,5H-
pyrido[3,2,1-ij]quinoline-9-carbonyl)terephthalic acid (29). 8-hydroxyjulolidine (3.00 
g, 15.85 mmol) was dissolved in toluene 45 mL, heated to 60 oC with an oil bath, and 
pounded trimellitic anhydride (3.65 g, 19.02 mmol) was added with magnetic stirring. The 
mixture was refluxed for 24 h and cooled. The residue was filtered off, washed with toluene 
(3×7.5 mL), dissolved in MeOH (45 mL) refluxed for 10 minutes. Then acetic acid (15 
mL) was added and the mixture was evaporated to dryness. Crystalline solid was refluxed 
with MeOH (30 mL) for 2 h and kept at 4 oC overnight. The crystals formed were filtered 
off and washed with MeOH (7.5 mL) to give the product as a yellow crystalline solid (1.90 
g, 20 % yield). 1H NMR (400 MHz, DMSO-d6) δ 13.40 (s, 4H), 12.83 (d, J = 13.0, 2.8 Hz, 
2H), 8.47 (s, 1H), 8.19 (d, J = 8.1 Hz, 1H), 8.15 – 8.09 (dd, 1H), 8.04 (dd, J = 8.7, 2.8 Hz, 
1H), 7.79 (s, 1H), 7.48 (dd, J = 8.2, 2.9 Hz, 1H), 6.40 (dd, J = 12.8, 2.7 Hz, 2H), 3.34 (s, 




13C{1H} NMR (101 MHz, DMSO-d6) δ 197.3, 197.1, 167.0, 166.7, 166.6, 166.6, 160.3, 
160.2, 149.5, 149.5, 144.3, 140.6, 134.2, 133.9, 133.0, 131.9, 131.2, 130.8, 130.6, 130.4, 
130.0, 130.0, 128.8, 128.7, 113.2, 108.6, 108.6, 105.1, 105.1, 49.9, 49.4, 49.1, 27.1, 21.5, 
20.5, 20.0. HRMS (ESI-TOF) m/z: [M + H] + Calcd for C21H20NO6 382.1285; Found 
382.1286 and 382.1289. 
Synthesis of isomers 11-methoxy-3'-oxo-2,3,6,7-tetrahydro-1H,3'H,5H-
spiro[benzo[5,6]chromeno[2,3-f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-5'-
carboxylic acid  and 11-methoxy-3'-oxo-2,3,6,7-tetrahydro-1H,3'H,5H-
spiro[benzo[5,6]chromeno[2,3-f]pyrido[3,2,1-ij]quinoline-9,1'-isobenzofuran]-6'-
carboxylic acid (30). The direct condensation with 1:1 MSA/TFA gave 60 % yield of 1:1 
5’ and 6’ carboxy isomers. Started with 100 mg of the 8-hydroxybenzophenone resulted in 
60 mg of the dye. Rf 0.35 (9:1:0.5 MeOH/DCM/HCOOH). 1H NMR (400 MHz, Methanol-
d4) δ 8.77 (s, 1H), 8.19 (d, J = 6.9 Hz, 5H), 8.04 (dd, J = 9.0, 5.0 Hz, 2H), 7.72 (d, J = 8.9 
Hz, 2H), 7.65 (s, 1H), 7.46 (dd, J = 8.9, 7.4 Hz, 2H), 7.11 (d, J = 7.9 Hz, 1H), 6.94 (ddd, J 
= 8.9, 2.4, 0.9 Hz, 2H), 6.65 (d, J = 2.4 Hz, 1H), 6.57 (d, J = 2.3 Hz, 1H), 6.49 (s, 1H), 6.43 
(s, 1H), 3.36 (dq, J = 18.3, 6.6 Hz, 8H), 3.16 (d, J = 6.9 Hz, 6H), 2.93 (m, J = 6.0 Hz, 4H), 
2.53 (ddt, J = 16.0, 10.2, 6.0 Hz, 4H), 1.98 (q, J = 6.0 Hz, 4H), 1.82 (q, J = 6.2 Hz, 4H). 
13C{1H} NMR (101 MHz, MeOD) δ 166.4, 159.4, 159.4, 133.8, 132.1, 130.9, 125.6, 125.4, 
117.3, 114.7, 114.6, 105.6, 105.3, 104.9, 78.2, 77.9, 77.6, 54.2, 50.6, 50.5, 50.2, 50.1, 27.2, 
20.5, 20.5, 19.6, 19.5. HRMS (ESI-TOF) m/z: [M + H] + Calcd for C32H26NO6 520.1755; 








f]pyrido[3,2,1-ij]quinolin-4-ium (8-NHS). Compound 30 (68 mg, 0.13 mmol), DMAP 
(79.95 mg, 0.65 mmol) and TEA (0.091 mL, 0.65 mmol) were dissolved in dry DCM (5 
mL). DSC (67.06 mg, 0.26 mmol) was added and the reaction stirred for 2 h. The reaction 
was quenched with AcOH (0.075 mL, 1.31 mmol) and the solution was directly loaded 
onto an equilibrated flash chromatography column and eluted with 0.5% HCOOH in 
CHCl3/MeOH 98/2 to afford the pure compound (54 mg, 80%). Rf 0.22 (98:2:0.5 
MeOH/DCM/HCOOH). 1H NMR (400 MHz, DMSO-d6) δ 8.58 (dd, J = 1.5, 0.7 Hz, 1H), 
8.30 – 8.25 (m, 2H), 8.22 (s, 2H), 8.11 – 8.04 (m, 2H), 7.89 (dd, J = 9.0, 1.1 Hz, 2H), 7.59 
(t, J = 1.0 Hz, 1H), 7.43 (d, J = 8.9 Hz, 2H), 7.35 (dd, J = 8.0, 0.7 Hz, 2H), 7.04 (dt, J = 
8.9, 2.5 Hz, 2H), 6.27 (dd, J = 6.0, 2.4 Hz, 2H), 6.07 (d, J = 8.3 Hz, 2H), 3.32 (d, J = 5.9 
Hz, 4H), 3.20 (t, J = 5.6 Hz, 4H), 3.17 – 3.09 (m, 4H), 2.97 – 2.89 (m, 4H), 2.63 (s, 8H), 
2.03 – 1.94 (m, 4H), 1.81 (dd, J = 11.3, 5.7 Hz, 4H), 1.18 (s, 6H). 13C{1H} NMR (101 
MHz, DMSO-d6) δ 208.8, 174.4, 173.5, 173.3, 169.3, 166.7, 166.6, 163.7, 158.4 158.3, 
155.4, 155.3, 151.6, 151.5, 145.6, 145.6, 144.4, 144.4, 137.1, 134.2, 133.0, 133.0, 132.5, 
132.5, 131.5, 131.3, 127.5, 126.3, 125.9, 125.7, 124.2, 124.0, 123.9, 118.8, 118.7, 116.4, 
116.4, 116.2, 106.9, 106.9, 106.4, 106.4, 106.3, 105.1, 105.0, 103.5, 103.5, 85.4, 69.0, 56.3, 




25.7, 21.6, 21.0. HRMS (ESI-TOF) m/z: [M + H] + Calcd for C36H29N2O8 617.1918; Found 
617.1922 and 617.1914. 
UV−Vis Absorption and Fluorescence Spectroscopy. UV−vis spectra were collected 
using a Cary 50 UV−vis spectrophotometer at rt using a reduced- volume 1 cm quartz 
cuvette. Fluorescence spectra were collected on a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies). All absorption spectra were reference 
corrected. Fluorescence spectra were corrected for the wavelength-dependent response of 
the R928 photomultiplier tube using a manufacturer-generated correction file. Quantum 
yields were reported as the average of multiple measurements using multiple references. 
EEMs were collected over various spectral regions, using 5 or 10 nm step sizes for emission 
and excitation. The band pass for excitation and emission was 5−10 nm.  
Cell Culture. The human PDAC cell line Capan-1 was obtained from Dr. Rosalie Sears’s 
laboratory at Oregon Health and Science University (OHSU) and was maintained in RPMI 
medium (Gibco) in a humid atmosphere at 37 °C with 5% CO2. All media were 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) 
penicillin/streptomycin. Cell viability was determined by Cell Titer-Blue assay. 
Monolayers of 104 Capan-1 cells were seeded in triplicate in 96-well plates and incubated 
with decreasing concentration from 100 µM of each compound in growth media containing 
10% FBS. After 24 h incubation time, 20 µL of Cell Titer-Blue reagent was added into 
each well and culture cells were incubated for additional 2 h. Fluorescence intensity in each 




maximal inhibitory concentrations (IC50 determined by interpolating values in the graph 
(% cell viability vs fluorophore concentration).  
In Vitro Live Cell Imaging. Monolayers of 104 Capan-1 cells were seeded in triplicate in 
eight-well plates and incubated for 24 h in growth medium containing 10% FBS and were 
allowed to attach. For subcellular colocalization experiments, the medium was extracted 
and cells were washed with phosphate-buffered saline (PBS), and phenol red-free growth 
medium was added to each well. Organelle trackers were added to each well, and incubated 
with the fluorophore of interest (final concentration 0.5 µM) for 1 h. Cells were washed 
with PBS and fixed with 2% paraformaldehyde (PFA). Fluorescence microscopy was 
carried out using a Zeiss inverted microscope with an Axioscan fluorescence camera for 
imaging. The final concentration of organelle trackers used were as follows: DAPI 0.5 µM, 
Mito-tracker green 0.5 µM, and ER-tracker green 1 µM.  
Fluorophore-labeled Antibodies. Compound 8 was conjugated to donkey anti-mouse 
antibody (Jackson ImmunoResearch) for immunofluorescence microtubule imaging. The 
antibody was buffer exchanged into 1× phosphate buffered saline (PBS) and pH adjusted 
to 8.3 with 35 mM disodium phosphate. The conjugation reactions were set up with 
fluorophore and antibody mixed at a 10:1 molar ratio for immunofluorescence microtubule 
imaging measurements. The fluorophore-antibody conjugation reactions were rocked 
gently at rt protected from light for 3 hr and were washed and concentrated in 10 kDa 




which was determined using an absorbance spectrometer (SpectraMax M5 Microplate 
Reader). 
Ex vivo Staining of PDAC tissue. The initial wash to remove excess OCT was done by 
covering each tissue sample with PBS. After 2 min, it was removed with vacuum. The 
tissue samples were fixed with 2% PFA at rt. for 15 min and washed 3× using PBS with 
0.1% Tween-20 for 5 min. Slides were incubated with fluorophore formulation, (10% 
dimethyl sulfoxide DMSO (control) or 10% DMSO fluorophore solution (dependent on 
specific concentration of fluorophore), 5% Kolliphor EL, 85% of 75/25 serum/PBS) for 40 
min at rt. Slides were covered to prevent photobleaching. Excess fluorophore was removed 
through two 5 min rinses with PBS. Fluorophore post-fixing was done using 2% PFA for 
15 min and washed 1× with PBS for 5 min. After removing excess PBS samples were 
mounted with fluoromount. The coverslip was placed onto tissue, making sure no air 
bubbles were present. The coverslips were sealed with colorless nail polish. The slides 
were stored at 20 ºC. Images were acquired using Zeiss Axioscan Z.1 slide scanner (Carl 
Zeiss) at 20× magnification. The fluorescence signal was optimized at the start of the study 
to not oversaturate the signal. For a standardized comparison, the power of Colibri 7 light 
source and integration times of the Hamamatsu ORCA Flash4 camera (Hamamatsu 
Photonics) were kept constant for all samples. The imaging was performed on slides 
overnight after staining with identical image acquisition settings. 
Immunofluorescence Labeling.  U2OS Cells were pre-extracted with 0.5% Triton X-100 
in PEM (100 mM PIPES buffer pH 7.0, 1 mM EGTA and 1 mM MgCl2) for 20 s, fixed 




for 90 s, washed with PBS before fixing with 3% glutaraldehyde in PEM 15 min. Cells 
were washed with PBS (3 × 5 min), then reduced with 10 mM sodium borohydride for 10 
min, washed again with PBS (3 × 5 min), and blocked with 5% bovine serum albumin 
(BSA) in PBS. Cells were incubated with bovine alpha-tubulin mouse primary antibody 
(Thermo Fisher Scientific) at 2 µ gml−1 in BSA for 4 h at rt and washed with PBS (3 × 5 
min). Lastly, cells were incubated with fluorophore-labeled donkey anti-mouse secondary 
antibody at 0.2 µM fluorophore concentration in PBS for 30 min at rt protected from light 
and washed with PBS (3 × 5 mins).22 Images were acquired on an Axio Observer inverted 
fluorescence microscope (Zeiss, Thornwood, NY) at 20× magnification. A PhotoFluor II 
was used and filtered using a 545 ± 12.5 bandpass excitation filter. Fluorescence images 
were collected using an Axiocam 506 camera (Zeiss), where a 605 ± 35 nm bandpass 
emission filter was used for image collection. 
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Chapter 4: Synthesis of Near Infrared Cyanine-Xanthene Hybrid Probes  
ABSTRACT 
Dyes that are active in the near infrared region (NIR, >700 nm) have been of great 
interest in various fields, including superresolution imaging and biomedical imaging as 
contrast agents. The xanthene dyes comprise some of the most common fluorophores such 
as fluorescein and rhodamine; however, they are not active in the NIR region. Owing to 
their favorable photophysical properties such as high molar absorbance, good water 
solubility and excellent quantum yields, xanthene scaffolds are among the most common 
labeling agents used in biological applications. Cyanine dyes are one type of the widely 
employed fluorophores for NIR fluorescent probe design. Xanthene chromophore 
functionalized with cyanine groups containing different lengths of their polymethine chain 
can be used to create a cyanine-xanthene based library of NIR fluorescent probes with 
enhanced photophysical properties for biological applications. There have been few studies 
that have explored the systematic chemical modification of members of a class of 
fluorophores for selective uptake by specific tissue or cell types using physiochemical 
predictors. Thus, the synthesis of the cyanine-xanthene hybrids will provide an 
understanding of structure activity relationship profiles for tissue and cellular specific 
uptake. The ability to correlate molecular structure of imaging agents and tissue-specific 
uptake could solve unmet clinical needs of NIR imaging agents that are inherently tissue-






Xanthene dyes exhibit lmax absorption and emission in the visible spectral region 
despite their relatively small molecular size (Figure 1).1 This is achieved by small bond 
length alternation (BLA) originating from the contributions of resonance structures.1 
Xanthene dyes are among the most commonly used class of fluorescent dyes in bioimaging. 
Fluorescein is a particularly useful dye for biological purposes for several reasons: the dye 
is very soluble in water, it has a high extinction coefficient (8 ×104 M-1cm-1) and high 
quantum yield (0.92).2 Derivatives of fluorescein are readily synthesized and that allow for 
the utilization of the dye in many applications including pH sensing, tracer agents, laser 
dyes, labeling agents in biology.2-7 
 
 
Figure 1. The xanthene core structure and common xanthene-based dyes showing possible sites for 
modification (blue numbers). 
 
However, xanthene dyes typically possess small Stokes shifts and are not active in 
the near infrared (NIR) region. Strategies for red-shifting xanthene dyes for biodiagnostics 
and imaging applications have been an active area of investigation for many years.8 




withdrawing groups such as cyano9 or trifluoromethyl,10 extending annulation, extending 
π-conjugation, replacement of the bridging oxygen-atom by carbon,11 phosphorus,6 sulfur,7 
or silicon,12 tellurium,13 selenium,14 and annulation (Figure 2). 5,8,15,16 Our group has been 
focused on annulation as one strategy to red-shift the xanthene dyes. 3,8,15-17  
 
 
Figure 2. The xanthene backbone and three possible sites for annulation. 
 
The annulation of xanthene is advantageous due to the low synthesis cost, high 
optical sensitivity, and excellent physicochemical properties for application in cell and 
tissue biological studies. These benzo-annulated xanthene (Figure 2) exhibit various sites 
for potential modification to generate new series of fluorescent dyes with different 




changes for the optimization of optical and/or biological properties such as inherent tissue-
specific in vivo targeting and malignant cell-specific ex vivo imaging.16,18 
An alternative strategy to synthesize NIR-active xanthene fluorophores employed 
in this project is the extension of the π-conjugated system on the xanthene backbone by 
attaching a cyanine moiety (Figure 3).19 Cyanine dyes are considered as a main source of 
organic long-wavelength fluorophores, providing excitation bands in the range 600-900 
nm.20 The red shifting of cyanine dyes is easily achieved by addition of a vinyl group (-
CH=CH-) to the polymethine chain.21 The ease of tuning the photophysical properties, 
sharp near infrared absorption and emission bands and large molar absorptivity have led to 
the much interest of using the cyanine moiety.22 Indocyanine green (ICG) is the first Food 
and Drug Administration (FDA) approved cyanine-based fluorophore for clinical use.22 
Despite great advances in the development of cyanine-based fluorescent probes as imaging 
fluorophores, improvement in the photophysical properties of cyanine fluorophores 
remains necessary.23 Some drawbacks of cyanine dyes are known, and these include 
limited stability in the presence of strong nucleophiles, photooxidation, and aggregation in 






Figure 3. Benzo[c]xanthene functionalized with a cyanine moiety to afford cyanine-xanthene hybrids. 
  
Rhodamine dyes functionalized with cyanine dyes have shown NIR absorption and 
emission spectral properties, as well as increased quantum yields and molar absorption 
coefficient values when compared to the classical rhodamine dyes.23 It has been 
hypothesized that the xanthene moiety could preserve far red optical properties, relatively 
high quantum yields and large Stokes shift where the cyanine moiety could enhance and 
achieve the desired NIR optical properties. Based on this design strategy, a library of ten 
compounds (Figure 4) will be synthesized that are expected to show synergistic 






Figure 4. A library of cyanine-xanthene hybrid probes. 
 
RESULTS AND DISCUSSION 
 Density Functional Theory (DFT) calculations 
Molecular orbital calculations were performed using Time Dependent Density Functional 
Theory (TD-DFT) at B3LYP/6-31G level the Gaussian 09 software package.  These 
calculations were done in order to predict the photophysical properties of the proposed 
cyanine-xanthene hybrid dyes. These predictions were useful in the preliminary selection 
to synthesize a focused library of compounds. The preliminary calculations from selected 
representative showed that when n=1 on the polymethine chain (Figure 5) the absorption 
of the probe is ~660 nm which is much closer to desired NIR region (typically experimental 
absorption wavelength >50nm than calculated).  Based on DFT calculations, the first 
compound targeted for synthesis was 6 because its calculated absorption maximum is ~660 








Figure 5. Calculated absorption wavelength of proposed cyanine-xanthene hybrid probes. 
 
Strategy 1: First synthesize the cyanine moiety. 
The cyanine-xanthene hybrids would be synthesized in 5 to 6 steps (Scheme 1). The initial 
step involved the formation of a phosphonium salt of 3-methoxybenzylbromide (12) from 
3-methoxybenzylbromide (11) which was used as a crude product in the subsequent Wittig 
reaction with aldehyde 13, followed by demethylation of methoxy 14 with HBr. Ortho 
acylation of phenol 15 with phthalic anhydride (16) afforded the functionalized cyanine 
hydroxybenzophenone hybrid building block 17 that could be condensed with 1,8- 
dihydroxynaphthalene derivatives based on 18. This would give the desired cyanine-
xanthene hybrid dye in the lactone or carboxylate form such as 19. Subsequent Fisher 
esterification with MeOH catalyzed by either H2SO4 or HCl, would afford the methyl ester 
derivatives, 6. The acid condensation to synthesize 19, showed the hydrolysis products 15 




























To address the acid hydrolysis problem from the first synthetic strategy (Scheme 1), an 
alternative was proposed to first synthesize the –C-O bridge of the xanthene chromophore. 
The cyanine-xanthene hybrid probes would be synthesized in 7-8 steps. First, the –C-O 
bond bridge was formed from a copper catalyzed Ullmann type reaction between methyl 
3-iodobenzoate (20) and 3-dimethylaminophenol (21) to afford 22. The methyl ester on 
one of diaryl ether derivative, was reduced using NaBH4 to afford 23. The bromination of 
phenol 23 using PBr3 would resulted in 24. Oxidation of 24 using DMSO and Na2CO3 
yielded aldehyde 25. The nucleophilic addition of 26 gave the extended –C-O xanthene 
bridge framework. Direct acylation with 16 would result in the benzophenone framework 
28 with subsequent ring closing step catalyzed by a Lewis acid ZnCl2 to give the final 
product 28. The acylation reaction with phthalic anhydride to synthesize 20 showed only 

















Scheme 2. First synthesize the –C-O bridge of xanthene chromophore. 
 
 





The cyanine-xanthene hybrid fluorophore would be synthesized in 4-5 steps by starting 
with an intact xanthene chromophore to address challenges from Schemes 1 and 2. First, 
the resorcinol benzophenone (30) was synthesized from basic hydrolysis of fluorescein 
(29). The direct condensation between 30 and 18 afforded a benzo[c]xanthene dye 31. The 
benzo[c]xanthene 31 was functionalized with triflate to give (32) for subsequent cross-
coupling reaction with a conjugated alkene 33, to give the final cyanine-xanthene hybrid 
probe, 34. The coupling reaction afforded the cyanine-xanthene hybrid dye as a mixture. 
There is need for reaction optimization. 









General. Unless otherwise indicated, all commercially available starting materials 
were used directly without further purification. Silica gel Sorbent Technologies 32-63 µm 
was used for flash column chromatography. MS (HRMS, ESI) spectra were collected using 
Agilent 6244 time-of-flight LCMS with diode array detector VL+. All the LC-MS 
chromatograms and spectra are in Appendix B. 
Synthesis of bromo(3-methoxybenzyl)triphenyl-l5-phosphane (12). To a 
solution of 1-(bromomethyl)-3-methoxybenzene in toluene was added a solution of PPh3 
in toluene. After being heated at reflux for 5 h, the reaction mixture was cooled at rt and a 
first crop of product was collected by filtration. The filtrate was refluxed for additional 5 h 
and a second crop of product precipitated. The collected crops were used in the next 
reaction without any further purification. 
Synthesis of (E)-2-((E)-3-(3-methoxyphenyl)allylidene)-1,3,3-
trimethylindoline (14). Under Ar atmosphere, n-BuLi (1.6 M, 6.18 mL, 10.47 mmol) was 
slowly added to a solution of 12 (5.0 g, 10.79 mmol) in THF (23 mL) at 78 oC. The resulting 
reddish solution was allowed to warm at rt. Fisher’s aldehyde in THF (13) (2.17 g, 10.79 
mmol) was added dropwise and the reaction mixture was stirred for overnight, diluted with 
ice-cold H2O (200 mL) and stirred for an additional hour. The aqueous layer was extracted 
with EtOAc; the combined organic layers were washed with H2O and dried. The product 
was separated by flash column chromatography on SiO2 using hexanes/ethyl acetate 95/5 







yl)phenol (15). Hydrogen bromide (HBr) (57.99 mL, 501.93 mmol) was added to 14 
(16.73 mmol) in glacial acetic acid (same volume as HBr). The solution was heated to 
reflux for 15 h and allowed to cool to rt. The mixture was diluted with H2O (same volume 
as HBr) and concentrated under reduced pressure. After cooling the solution was 
neutralized to about pH 5-6 with 30 % aq. NaOH. The aqueous phase was extracted with 
DCM (3 X 50 mL) and the organic layers were washed with brine and dried over Na2SO4. 
The solvent was evaporated under reduced pressure. The product was separated by flash 
column chromatography on SiO2 using hexanes/ethyl acetate 5/1 (0.67 g, 20%). HRMS 
(ESI-TOF) m/z: [M + H]+ Calcd for C20H21NO 292.1696; Found 292.1623. 
 
Synthesis of 2-(2-hydroxy-4-((E)-3-((E)-1,3,3-trimethylindolin-2-
ylidene)prop-1-en-1-yl)benzoyl)benzoic acid (17). Under Ar atmosphere anhydrous 
MeCN was added to 15 (200 mg, 686.36 µmol). Triethylamine (95.67 µL, 686.36 µmol) 
and ZnCl2 (93.54 mg, 686.36 µmol) were added to the solution. The solution was let to stir 
for 1 h at rt. phthalic anhydride (111.83 mg, 754.99 µmol) was added to the stirring 
solution. The reaction was allowed to stir overnight under reflux. The MeCN was removed 
under reduced pressure. The product was isolated by crystallization using chilled MeOH 






1-en-1-yl)-3'H-spiro[benzo[c]xanthene-7,1'-isobenzofuran]-3'-one (19). Compound 17 
(200 mg, 45.51 µmol) and 1,8-dihydroxynaphthalene (7.29 mg, 45.51 µmol) were 
combined and 150 µL of 1:1 methanesulfonic acid : trifluoroacetic acid was added. The 
reaction was stirred overnight at 80 oC. After the reaction was cooled, the reaction was 
poured on 500 µL of iced distilled H2O. The crude reaction was filtered by vacuum 
filtration. No product was observed, instead 15 was the main product peak in liquid 
chromatography- mass spectrometer. 
Synthesis of methyl 3-(3-(dimethylamino)phenoxy)benzoate (22). In an oven 
dried microwave tube add CuI (138.83 mg, 728.93 µmol), 2-Picolinic acid (179.49 mg, 
1.46 mmol), 20 (1.91 g, 7.29 mmol), 21 (1.0 g, 7.29 mmol) and K3PO4 (3.09 g, 14.58 
mmol). The reaction was vacuumed and back filled with dry N2 for 3 to 5 times, and sealed 
immediately with a Teflon cap. Anhydrous DMSO was added (7 mL). The reaction was 
stirred at 85 oC for 24 h. After reaction had cooled down to rt, 50 mL distilled H2O was 
added and the product was extracted with DCM three times (50 mL each). The product was 
isolated by flash chromatography on SiO2 using hexanes/ethyl acetate 95/5 (1.37 g 69 %). 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H17NO3 272.1281; Found 272.1276. 
 
Synthesis of (3-(3-(dimethylamino)phenoxy)phenyl)methanol (23). Anhydrous 
THF was added to 22 (1.0 g, 3.69 mmol) under dry N2. NaBH4 (766. 91 mg, 20.27 mmol) 
was added, as the reaction was stirring 3 mL of MeOH was added dropwise under reflux 




down to rt the pH was adjusted to 7 by using 1M HCl. The solution was extracted four 
times with EtOAc, dried with Na2SO4, filtered and evaporated under reduced pressure to 
give a clean product (980 mg, 98 %). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C15H17NO2 244.1332; Found 244.1277. 
Synthesis of 3-(3-(bromomethyl)phenoxy)-N,N-dimethylaniline (24). 
Compound 23 (1.20 g, 4.93 mmol) was dissolved in 20 mL anhydrous DCM under N2. The 
solution was chilled in an ice bath for 30 mins before adding PBr3 (0.42 mL, 4.48 mmol) 
and the reaction was stirred for an additional 10 mins before removing ice bath. The 
reaction was left to stir for two hours and quenched by adding saturated Na2CO3 (20 mL) 
with slow addition. The product was extracted by ethyl ether three times (40 mL each). The 
combined organic fractions were washed with Na2S2O3 (20 mL) and saturated brine (20 
mL). The solution was dried with Na2SO4, filtered and concentrated under reduced pressure 
to give the crude product which was used without further purification (130 mg, 9.47%). 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C15H16BrNO 306.0488; Found 306.0403. 
Synthesis of 3-(3-(dimethylamino)phenoxy)benzaldehyde (25). Compound 24 
(130 mg, 424.55 µmol) and NaHCO3 (154.43 mg, 1.84 mmol) were combined in 30 mL of 
DMSO and heated to 150 °C for 4 h. The dark red solution was cooled and diluted into 105 
mL of 2 M HCl and stirred for 2 h. The aqueous material was extracted thoroughly with 
DCM eight times (15 mL each) and the solvents were removed to isolate the crude product 
which was used in the next reaction without further purification (109 mg, 84 %). HRMS 





indol-1-ium (27).  To a solution of the 25 (84.50 mg, 348.74 µmol) and the 26 (1.2 mmol) 
in anhydrous EtOH (10 mL) under a dry N2 atmosphere was added four drops of pyridine. 
After being stirred for 4 h at 78 oC, the mixture was cooled to rt. The removal of solvent 
under reduced pressure and purification by flash column chromatography on SiO2 yielded 
a 1:1 mixture of 25 and 26. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C27H29N2O+ 
397.2274; Found 397.2275. 
Synthesis of (E)-2-(3-(2-(2-carboxybenzoyl)-5-
(dimethylamino)phenoxy)styryl)-1,3,3-trimethyl-3H-indol-1-ium (28). Under Ar 
atmosphere anhydrous MeCN was added to 27 (26 mg, 65.40 µmol). Triethylamine (9.12 
µL, 65.40 µmol) and ZnCl2 (8.91 mg, 65.40 µmol) were added to the solution. The solution 
was let to stir for 1 h at rt. Phthalic anhydride (10.66 mg, 71.94 µmol) was added to the 
stirring solution. The reaction was allowed to stir overnight under reflux. The MeCN was 
removed under reduced pressure. There was no product peak in liquid chromatography- 
mass spectrometer (only starting material observed). 
Synthesis of 2-(2,4-dihydroxybenzoyl)benzoic acid (30). Fluorescein (29) (1.7 g, 
5.12 mmol) was dissolved in 12 mL of 50 % NaOH solution (w/v) and heated at 160 oC in 
an oil bath for 1 h. After cooling to rt, the mixture was poured into 80 mL of ice H2O, 
acidified with concentrated HCl, and allowed to stand at rt for 2 h. The precipitate was 
filtered and dried to afford the desired product as a beige powder (1.06 g, 80.3 %). HRMS 





3'-one (31).  Compound 30 (2.0 g, 7.75 mmol) and 1,8-dihydroxynaphthalene (1.96 g, 
12.24 mmol) were dissolved in 5 mL of methanesulfonic acid and 5 mL trifluoroacetic acid 
was added. The mixture was heated and stirred in an oil bath at 80 oC for 24 h.  The reaction 
mixture was allowed to warm to rt, poured into 50 mL of iced cold distilled H2O. The 
resulting precipitate was filtered, washed with DI H2O and air dried.  The compound was 
isolated by flash column chromatography on SiO2 using CH2Cl2/MeOH 9/1 (991 mg, 50 
%). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C24H14O5 383.0914; Found 383.1616. 
Synthesis of 3'-oxo-3'H-spiro[benzo[c]xanthene-7,1'-isobenzofuran]-1,10-diyl 
bis(trifluoromethanesulfonate) (32). Compound 31 (1.0 g, 2.62 mmol) was suspended in 
DCM (30 mL) and cooled to 0 °C. Pyridine (1.69 mL, 20.92 mmol) and 
trifluoromethanesulfonic anhydride (1.76 mL, 10.46 mmol) were added, and the ice bath 
was removed. The reaction was stirred at rt for 4 h. The crude product was subsequently 
diluted with H2O and extracted with DCM. The combined organic extracts were washed 
with (saturated CuSO4, brine), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The product was isolated by flash column chromatography on SiO2 using 
hexanes/ethyl acetate 8/2 (717 mg, 72 %). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C25H13F3O7S 515.0407; Found 515.0463. 
Synthesis of N,N-dimethyl-4-vinylaniline (33). An oven-dried round bottom flask 
was charged with methyltriphenylphosphonium bromide (8.62 g, 24.13 mmol) and 60 mL 
anhydrous THF and stirred under nitrogen. A 1.6 M solution of n-BuLi in hexanes was 




dimethylbenzaldehyde (2.0 g, 13.41 mmol) was added. After stirring overnight, the 
reaction was poured into 200 mL of hexanes. The suspension was filtered through Celite 
and concentrated under reduced pressure. The residue was taken up in EtOAc and filtered 
through a thin pad (2 cm) of alumina. Removal of solvents under reduced pressure provided 
1.68 g of 33 (1.68 g, 84 %) which was judged to be pure by 1H NMR. HRMS (ESI-TOF) 
m/z: [M + H]+ Calcd for C10H13N 148.1121; Found 148.1170. 
Synthesis of 1,10-bis((E)-4-(dimethylamino)styryl)-3'H-
spiro[benzo[c]xanthene-7,1'-isobenzofuran]-3'-one (34). In 25 mL round-bottomed 
flask; added successively was compound 32 (100 mg, 194.39 µmol), compound 33 (28.62 
mg 194.39 µmol), 1 mL DMF, 1 mL TEA, PPh3 (10.20 mg, 38.88 µmol) and palladium 
(4.36 mg, 19.44 µmol); under N2 protection. The reaction was heated to 120 oC overnight. 
Removal of solvent under reduced pressure showed the product peak in liquid 
chromatography-mass spectrometer with other side products. HRMS (ESI-TOF) m/z: [M 
+ H]+ Calcd for C34H25NO4 512.1856; Found 512.1912. 
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Chapter 5: Conclusion and Future Work 
Surgery remains the most effective cure for PDAC, whose survival rate is still very 
low (<5 %). Moreover, despite the curative nature of surgery most PDAC patients are left 
with residual tumor (>75 % of patients) due to the lack of contrast agents that can help to 
inform surgeons if they need to remove more tissue.  Intraoperative margin assessment has 
the potential to improve the outlook of PDAC patients after surgery by confirming clear 
margins (RO) with no microscopic tumor involvement. Microscopic tumor involvement 
(R1) after surgery increases the chances of locoregional recurrence of the disease thereby 
lowering the survival rate of patients after a curative PDAC surgery. 
In this work compound 12, with no targeting ligand, allowed for the visualization 
of PDAC in human tissue and the common precancer lesions of PDAC, PanIN. A 
streamlined procedure was developed enabling staining within 15 min as required by the 
intraoperative workflow. A Matlab code was developed to enable objective quantification 
of the effective contrast of 12 in PDAC tissue. The staining protocol optimization rendered 
the potential use of 12 during PDAC surgery for margin assessment to ensure complete 
resection of tumor. A regioisomer of 12 maintained PDAC selectivity. This strategy 
provides an assortment of PDAC selective probes with distinct photophysical properties.  
The motivation to synthesize benzoxanthenes functionalized with cyanines was to 
address the photophysical limitations of benzoxanthene mainly their absorption in the 
visible region where biomolecules like hemoglobin have strong absorption as well.  The 




revealed the challenge of using conventional acid condensation reaction conditions 
typically used in the synthesis of benzoxanthene, due to the possible hydrolysis of the 
cyanine moiety.  
Following the complete synthesis of the cyanine-xanthene hybrid library using the 
coupling method, the photophysical and chemical characterization (1H-NMR, 13C-NMR 
and HR-MS) will be performed. The hybrid library will be used for in vivo biodistribution 
study, the fluorophore with the highest pancreas tumor tissue signal-to-noise ratio (SBR) 
will be identified. Ex vivo screening to investigate the staining pattern of the hybrid dyes 
will be carried out on human PDAC tissue specimens from Origene Inc.  
Longer term goals of this study are to contribute to the visualization of PDAC and 
early precancer lesions during surgery to ensure complete removal of cancer. The cyanine-
xanthene hybrids will also allow for quantitative structure-activity relationship (QSAR) to 
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Figure A1.  Solutions of compounds 1-9 under various pH conditions. Sample concentration: 50 µM. 
Aqueous solutions contains 10% DMSO. 
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Table A1. Tabulated spectral properties of compounds 1-9 in aqueous buffer at pH 7.4. 
 
  
λmax abs λmax em Stokes Shift Extinction Coefficient Quantum Yield FWHM
(nm) (nm) (nm) (M -1·cm -1) (%) (nm)
1 520 580 60 29,927 0.17 51 163 8.07 ± 0.05
2 515 620 105 24,200 10.86 2628 161        
3 530 580 50 22,084 0.73 161 116        
4 530 610 80 29,327 1.56 458 104 8.14 ± 0.04
5 520 610 90 28,258 7.86 2221 118        
6 567 640 73 28,615 0.29 83 101        
7 538 630 92 24,978 6.26 1564 115 8.39 ± 0.06
8 535 640 105 24,075 8.18 1969 117        






Figure A3. Absorption spectra of pH- and solvent-dependent seminaphthorhodafluors (1, 4, and 7). (a-
c) Absorption spectra as a function of pH for 1 (a), 4 (b), and 7 (c). (d-f) Absorption spectra as a function of 
solvents including DMSO, MeOH, and phosphate pH 7.4 buffer for 1 (d), 4 (e), and 7 (f). Aqueous buffer 
solutions contain 10% DMSO and 12.5 mM HCl, phosphate buffer, or NaOH. Ratiometric absorption spectra 
were observed for 1, 4, and 7. Well defined isosbestic points indicate spectral changes result from acid-base 





















































































































































Figure A4. Excitation Emission Matrices (EEMs) of pH dependent seminaphthorhodafluors (1, 4, 
and 7). Aqueous buffer solutions contain 10% DMSO and 12.5 mM HCl, phosphate buffer, or NaOH. 

























Figure A5. Absorption spectra of pH- and solvent-independent seminaphthorhodafluors (2, 5, and 8). 
(a-c) Absorption spectra as a function of pH for 2 (a), 5 (b), and 8 (c). (d-f) Absorption spectra as a function 
of solvents including DMSO, MeOH, and phosphate pH 7.4 buffer for 2 (d), 5 (e), and 8 (f). Aqueous buffer 
solutions contain 10% DMSO and 12.5 mM HCl, phosphate buffer, or NaOH. No pH equilibria or 


















































































































Figure A6. Excitation Emission Matrices (EEMs) of pH independent seminaphthorhodafluors (2, 5, 


























Figure A7. Absorption spectra of pH-independent but solvent modest sensitive seminaphthorhodamines(3, 
6, and 9). (a-c) Absorption spectra as a function of pH for 3 (a), 6 (b), and 9 (c). (d-f) Absorption spectra as 
a function of solvents including DMSO, MeOH, and phosphate pH 7.4 buffer for 3 (d), 6 (e), and 9 (f). 
Aqueous buffer solutions contain 10% DMSO and 12.5 mM HCl, phosphate buffer, or NaOH. No pH 
equilibria behavior were observed for 3, 6, and 9, with moderate sensitivity to polarity with the longest 



















































































































Figure A8. Excitation Emission Matrices (EEMs) of pH independent seminaphthorhodamines (3, 6, and 9). 


























Figure A9. Calculated frontier molecular orbitals (HOMO and LUMO) for pH-dependent 







Figure A8. Calculated frontier molecular orbitals (HOMO and LUMO) for pH-independent 






Table A2. Calculated HOMO and LUMO energies and their energy gaps for compounds 1-9 cations and 1, 
4 and 7 neutral forms in the ground state. 
Compound Energy (eV) 
 HOMO LUMO Gap 
1 cation -8.8678 -5.9445 2.9234 
1 neutral -4.8924 -2.7190 2.1734 
4 cation -8.7242 -5.8726 2.8515 
4 neutral -4.7844 -2.6249 2.1595 
7 cation -8.3682 -5.5703 2.7979 
7 neutral -4.6982 -2.5626 2.1356 
2 cation -8.7005 -5.8775 2.8230 
5 cation -8.5152 -5.7349 2.7803 
8 cation -8.3818 -5.5932 2.7887 
3 cation -8.3974 -5.8013 2.5960 
6 cation -8.2648 -5.6669 2.5979 





Table A3. Calculated dihedral angles for cations 1-9 and for the neutral forms of 1, 4, and 7 at C(18-7-8-9) and 
C(7-8-9-10). 
Compound  (ϕ,  º)  
 C(18-7-8-9) C(7-8-9-10) 
1 cation -5.2 -0.9 
4 cation  -4.2 -0.4 
7 cation -4.9 -1.4 
2 cation -5.2 -1.2 
5 cation -4.6 -0.4 
8 cation -5.6 -3.1 
3 cation -5.5 -2.0 
6 cation -5.6 -1.9 
9 cation -4.5 0.2 
1 neutral -7.1 -10.4 
4 neutral -7.0 -10.5 







Table A4. Calculated bond lengths for cations and neutral forms of compounds 1, 4, and 7 from carbon 
atoms (6-7-8-9-10-11).  
Compound Bond Bond Length 




1 C6-C7 142 145 
C7-C8 143 140 
C8-C9 147 149 
C9-C10 141 138 
C10-C11 139 146 
4 C6-C7 141 144 
C7-C8 143 140 
C8-C9 147 149 
C9-C10 141 138 
C10-C11 139 146 
7 C6-C7 141 144 
C7-C8 143 140 
C8-C9 147 149 
C9-C10 141 138 






Figure A9. 1H NMR spectrum of compound 11. 
 
 






Figure A11. HR ESI positive mode spectrum of compound 11. 
  
Figure A12. 1H NMR spectrum of compound 20. 
CS01-003_160511231626 #12-15 RT: 0.25-0.30 AV: 4 NL: 1.50E4
T: FTMS - p ESI Full ms [50.00-2000.00]












































Figure A13. 13C NMR spectrum of compound 20. 
 
 
Figure A14. HR ESI positive mode spectrum of compound 20. 
LW08-53_160511230132 #10-20 RT: 0.22-0.38 AV: 11 NL: 4.37E4
T: FTMS - p ESI Full ms [50.00-2000.00]




















































Figure A17. HR ESI positive mode spectrum of compound 25. 
LW-08-42 #14-45 RT: 0.18-0.51 AV: 32 NL: 8.30E7
T: FTMS + p ESI Full ms [50.00-2000.00]


















































Figure A19. 13C NMR spectrum of compound 13. 
 
 












Figure A22. 13C NMR spectrum of compound 14. 
 
 
Figure A23. HR ESI positive mode spectrum of compound 14. 
CS01-001_160511225831 #12-28 RT: 0.21-0.51 AV: 17 NL: 4.73E3
T: FTMS + p ESI Full ms [50.00-2000.00]























































Figure A25. 13C NMR spectrum of compound 15. 
 







Figure A27. HR ESI positive mode spectrum of compound 15. 
 
  
Figure A28. 1H NMR spectrum of compound 16. 
CS-01-005F1 #7-27 RT: 0.11-0.49 AV: 21 NL: 4.43E5
T: FTMS + p ESI Full ms [50.00-2000.00]





















































Figure A30. 2D COSY NMR spectrum for compound 16. 
 
 
Figure A31. HR ESI positive mode spectrum of compound 16. 
LW-08-055 #14-22 RT: 0.25-0.34 AV: 9 NL: 4.19E6
T: FTMS + p ESI Full ms [50.00-2000.00]
























































Figure A34. 2D COSY NMR spectrum for compound 21. 
 
 
Figure A35. HR ESI positive mode spectrum of compound 21. 
MSV01-150-F7-11_160511181638 #7-52 RT: 0.11-0.96 AV: 46 NL: 2.97E4
T: FTMS + p ESI Full ms [50.00-2000.00]
























































Figure A38. 2D COSY NMR spectrum for compound 22. 
 
 
Figure A39. HR ESI positive mode spectrum of compound 22. 
LW-08-058 #19-42 RT: 0.26-0.50 AV: 24 NL: 1.83E7
T: FTMS + p ESI Full ms [50.00-2000.00]






















































Figure A42. 2D COSY NMR spectrum for compound 26. 
 
 
Figure A43. HR ESI positive mode spectrum of compound 26. 
MSV08-14-F15_160511181952 #21-26 RT: 0.38-0.43 AV: 6 NL: 7.81E6
T: FTMS + p ESI Full ms [50.00-2000.00]




























































Figure A46. 2D COSY NMR spectrum for compound 27. 
 
 
Figure A47. HR ESI positive mode spectrum of compound 27. 
lw-08-054f1 #10-27 RT: 0.17-0.38 AV: 18 NL: 1.09E7
T: FTMS + p ESI Full ms [50.00-2000.00]


























































Figure A50. 2D COSY NMR spectrum for compound 1. 
 
 
Figure A51. HR ESI positive mode spectrum of compound 1. 
LW-08-068 #19-20 RT: 0.30-0.32 AV: 2 NL: 1.69E6
T: FTMS + p ESI Full ms [50.00-2000.00]
































































Figure A54. 2D COSY NMR spectrum for compound 2. 
 
 
Figure A55. HR ESI positive mode spectrum of compound 2. 
 
L:\Data\Strongin\Ian\08069 10/22/18 17:14:30 08069
08069 #20-72 RT: 0.12-0.34 AV: 26 NL: 1.10E8
F: FTMS + p ESI Full ms [200.00-2000.00]

























































Figure A58. 2D COSY NMR spectrum for compound 4. 
 
 
Figure A59. HR ESI positive mode spectrum of compound 4. 
 
L:\Data\Strongin\Ian\08061 10/22/18 17:12:16 08061
08061 #19-55 RT: 0.12-0.29 AV: 19 NL: 1.73E8
F: FTMS + p ESI Full ms [200.00-2000.00]
















































Figure A60. 1H NMR spectrum of compound 5. 
 
 






Figure A62. 2D COSY NMR spectrum for compound 5. 
 
 
Figure A63. HR ESI positive mode spectrum of compound 5. 
L:\Strongin LAB\Lei\08-64 08/02/18 11:22:40 08-64
08-64 #47-107 RT: 0.41-0.71 AV: 31 NL: 2.97E6
F: FTMS + p ESI Full ms [200.00-2000.00]






















































Figure A65. 13C NMR spectrum of compound 7. 
 
 






Figure A67. HR ESI positive mode spectrum of compound 7. 
 
 
Figure A68. 1H NMR spectrum of compound 8.  
MSV08-140-F14-19_160511223740 #18-24 RT: 0.32-0.43 AV: 7 NL: 4.65E5
T: FTMS + p ESI Full ms [50.00-2000.00]

























































Figure A70. 2D COSY NMR spectrum for compound 8. 
 
 




LW08-063_160511223143 #12-27 RT: 0.21-0.49 AV: 16 NL: 1.31E5
T: FTMS + p ESI Full ms [50.00-2000.00]
















































Figure A72. 1H NMR spectrum of compound 29. 
 
 


















Figure A76. 13C NMR spectrum of compound 30. 
 
 















Figure A79. 13C NMR spectrum of compound 8-NHS. 
 
 






 Figure A81. Crystal structure of compound 21. Ellipsoid contours are at the 50% probability level. 
 
 
X-ray single-crystal experimental data for compound 21. 
 
Pink crystals of 21 were grown by solvent diffusion from chloroform, methanol and 
hexanes. The crystal structure was determined at T=90K from data collected to θmax=68.4° 
with Cu Kα radiation on a Bruker Kappa Apex-II diffractometer. 13,611 measured 
reflections yielded 3585 unique data (Rint=0.049), of which 2737 had I>2σ(I). C26H19NO4, 
FW=409.42, monoclinic space group P21/c, a=13.6561(14), b=7.5404(10), c=20.070(2)Å, 
β=106.046(5)°, V=1986.1(4) Å3, Z=4. Absorption corrections were by the multi-scan 
method. Nonhydrogen atoms were treated with anisotropic displacement parameters. All 
H atoms were visible in difference maps, but were placed in idealized positions except for 
that of the OH group, for which coordinates were refined.  Refinement yielded R=0.039 


































Δρmax=0.25eÅ-3, Δρmin=-0.21eÅ-3.  The CIF has been deposited at the Cambridge 
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Figure B13. HR ESI positive mode spectrum of compound 34. 
 
 
